#MolSigDB_pub_id MolSigDB_labels Number_citations Days_since_publication 17210693 NAKAMURA_CANCER_MICROENVIRONMENT_UP 11 2241 17210693 NAKAMURA_CANCER_MICROENVIRONMENT_DN 11 2241 17234769 WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP 14 2241 17234769 WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN 14 2241 17409455 WINTER_HYPOXIA_UP 34 2151 17409455 WINTER_HYPOXIA_DN 34 2151 17483347 PARENT_MTOR_SIGNALING_UP 7 2121 17483347 PARENT_MTOR_SIGNALING_DN 7 2121 17510386 PYEON_HPV_POSITIVE_TUMORS_UP 45 2121 17699763 NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP 5 2029 17699763 NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN 5 2029 18006812 PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP 12 1937 18006812 PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 12 1937 17308118 LU_TUMOR_VASCULATURE_UP 16 2210 17308118 LU_TUMOR_VASCULATURE_DN 16 2210 16424014 KORKOLA_EMBRYONAL_CARCINOMA_UP 39 2606 16424014 KORKOLA_EMBRYONAL_CARCINOMA_DN 39 2606 16424014 KORKOLA_TERATOMA_UP 39 2606 16424014 KORKOLA_TERATOMA_DN 39 2606 16424014 KORKOLA_YOLK_SAC_TUMOR_UP 39 2606 16424014 KORKOLA_YOLK_SAC_TUMOR_DN 39 2606 16424014 KORKOLA_CHORIOCARCINOMA_DN 39 2606 16424014 KORKOLA_SEMINOMA_UP 39 2606 16424014 KORKOLA_SEMINOMA_DN 39 2606 16585155 WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP 9 2516 16585155 WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN 9 2516 16585179 HOLLMAN_APOPTOSIS_VIA_CD40_UP 2 2516 16585179 HOLLMAN_APOPTOSIS_VIA_CD40_DN 2 2516 16618720 LIU_PROSTATE_CANCER_UP 29 2516 16618720 LIU_PROSTATE_CANCER_DN 29 2516 16618720 LIU_SOX4_TARGETS_UP 29 2516 16618720 LIU_SOX4_TARGETS_DN 29 2516 16651410 ONKEN_UVEAL_MELANOMA_UP 18 2486 16651410 ONKEN_UVEAL_MELANOMA_DN 18 2486 16651414 BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP 39 2486 16651414 BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN 39 2486 16707453 SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 42 2486 16707453 SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN 42 2486 16849537 DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_UP 41 2425 16849537 DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_DN 41 2425 16849555 FOURNIER_ACINAR_DEVELOPMENT_EARLY_UP 31 2425 16849555 FOURNIER_ACINAR_DEVELOPMENT_LATE_UP 31 2425 16849555 FOURNIER_ACINAR_DEVELOPMENT_LATE_DN 31 2425 16849564 NAM_FXYD5_TARGETS_DN 11 2425 16849584 FRASOR_TAMOXIFEN_RESPONSE_UP 37 2425 16849584 FRASOR_TAMOXIFEN_RESPONSE_DN 37 2425 16885346 KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP 29 2394 16885346 KIM_RESPONSE_TO_TSA_AND_DECITABINE_DN 29 2394 16912175 SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP 25 2394 16912175 SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN 25 2394 17047040 WATANABE_COLON_CANCER_MSI_VS_MSS_UP 18 2333 17047040 WATANABE_COLON_CANCER_MSI_VS_MSS_DN 18 2333 17145885 KOBAYASHI_EGFR_SIGNALING_6HR_DN 20 2272 16478745 SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 267 2575 16478745 SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_DN 267 2575 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_UP 13 2363 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN 13 2363 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_UP 13 2363 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_DN 13 2363 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP 13 2363 16741228 GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN 13 2363 16424048 CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP 15 2606 16424048 CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN 15 2606 17297441 IGARASHI_ATF4_TARGETS_DN 8 2060 17043644 ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP 22 2151 17043644 ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN 22 2151 16849537 DAVICIONI_MOLECULAR_ARMS_VS_ERMS_UP 41 2425 16849537 DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN 41 2425 16849537 DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP 41 2425 16849537 DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN 41 2425 16849537 DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP 41 2425 16849537 DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN 41 2425 16912175 SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP 25 2394 16912175 SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN 25 2394 17389037 TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP 44 NaN 17389037 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP 44 NaN 17389037 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN 44 NaN 17389037 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP 44 NaN 17389037 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN 44 NaN 17389037 TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_UP 44 NaN 17389037 TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP 44 NaN 17389037 TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_DN 44 NaN 17389037 TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP 44 NaN 17389037 TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN 44 NaN 17430594 CHANDRAN_METASTASIS_TOP50_UP 48 NaN 17430594 CHANDRAN_METASTASIS_TOP50_DN 48 NaN 18070364 WILCOX_PRESPONSE_TO_ROGESTERONE_UP 1 NaN 18070364 WILCOX_PRESPONSE_TO_ROGESTERONE_DN 1 NaN 16785517 FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP 14 2425 16785517 FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN 14 2425 17878328 GARY_CD5_TARGETS_UP 3 1968 17878328 GARY_CD5_TARGETS_DN 3 1968 18025224 ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP 13 1907 18025224 ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN 13 1907 17500590 SAMOLS_TARGETS_OF_KHSV_MIRNAS_DN 65 2121 16474848 HOOI_ST7_TARGETS_UP 6 2455 16474848 HOOI_ST7_TARGETS_DN 6 2455 16636670 PRAMOONJAGO_SOX4_TARGETS_UP 18 2363 16636670 PRAMOONJAGO_SOX4_TARGETS_DN 18 2363 17971902 PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP 17 1968 17971902 PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN 17 1968 16533756 PIEPOLI_LGI1_TARGETS_UP 0 2516 16533756 PIEPOLI_LGI1_TARGETS_DN 0 2516 17606841 THUM_SYSTOLIC_HEART_FAILURE_UP 97 2060 17606841 THUM_SYSTOLIC_HEART_FAILURE_DN 97 2060 16990782 CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP 5 2302 16990782 CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN 5 2302 17344918 CORRE_MULTIPLE_MYELOMA_UP 28 2121 17344918 CORRE_MULTIPLE_MYELOMA_DN 28 2121 16932341 HUTTMANN_B_CLL_POOR_SURVIVAL_UP 10 2333 16932341 HUTTMANN_B_CLL_POOR_SURVIVAL_DN 10 2333 17252012 DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN 16 2182 16990782 CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP 5 2302 17713554 DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP 8 1968 17713554 DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN 8 1968 16205643 LIU_CMYB_TARGETS_UP 10 2575 NaN LIU_VMYB_TARGETS_UP NaN NaN 16205643 LIU_TARGETS_OF_VMYB_VS_CMYB_UP 10 2575 16205643 LIU_TARGETS_OF_VMYB_VS_CMYB_DN 10 2575 16288205 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP 74 2516 16288205 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN 74 2516 16288205 CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP 74 2516 16288205 CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN 74 2516 16288205 CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP 74 2516 16288205 CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN 74 2516 16491124 DOANE_BREAST_CANCER_CLASSES_UP 50 2455 16491124 DOANE_BREAST_CANCER_CLASSES_DN 50 2455 16491124 DOANE_RESPONSE_TO_ANDROGEN_UP 50 2455 16491124 DOANE_RESPONSE_TO_ANDROGEN_DN 50 2455 16491124 DOANE_BREAST_CANCER_ESR1_UP 50 2455 16491124 DOANE_BREAST_CANCER_ESR1_DN 50 2455 NaN WANG_RESPONSE_TO_ANDROGEN_UP NaN NaN 16751804 WANG_RESPONSE_TO_FORSKOLIN_UP 7 2302 16799645 TIMOFEEVA_GROWTH_STRESS_VIA_STAT1_DN 11 2272 16819509 LAIHO_COLORECTAL_CANCER_SERRATED_UP 6 2241 16819509 LAIHO_COLORECTAL_CANCER_SERRATED_DN 6 2241 16862182 BORCZUK_MALIGNANT_MESOTHELIOMA_UP 4 2241 16862182 BORCZUK_MALIGNANT_MESOTHELIOMA_DN 4 2241 17728400 ROY_WOUND_BLOOD_VESSEL_UP 26 1998 17728400 ROY_WOUND_BLOOD_VESSEL_DN 26 1998 17173069 GRABARCZYK_BCL11B_TARGETS_UP 8 2121 17173069 GRABARCZYK_BCL11B_TARGETS_DN 8 2121 16772382 NEWMAN_ERCC6_TARGETS_UP 22 2455 16772382 NEWMAN_ERCC6_TARGETS_DN 22 2455 17088532 HORIUCHI_WTAP_TARGETS_UP 3 2302 17088532 HORIUCHI_WTAP_TARGETS_DN 3 2302 17039238 GAL_LEUKEMIC_STEM_CELL_UP 12 2272 17039238 GAL_LEUKEMIC_STEM_CELL_DN 12 2272 16909099 CHOI_ATL_CHRONIC_VS_ACUTE_DN 9 2210 17072343 BASAKI_YBX1_TARGETS_UP 7 2151 17072343 BASAKI_YBX1_TARGETS_DN 7 2151 17297461 NOJIMA_SFRP2_TARGETS_UP 24 2060 17297461 NOJIMA_SFRP2_TARGETS_DN 24 2060 17297452 WIKMAN_ASBESTOS_LUNG_CANCER_UP 11 2060 17297452 WIKMAN_ASBESTOS_LUNG_CANCER_DN 11 2060 17334389 RODRIGUES_DCC_TARGETS_DN 15 2029 17334389 RODRIGUES_NTN1_TARGETS_UP 15 2029 17334389 RODRIGUES_NTN1_TARGETS_DN 15 2029 17452977 WANG_LMO4_TARGETS_UP 9 1998 17452977 WANG_LMO4_TARGETS_DN 9 1998 17452977 WANG_CLIM2_TARGETS_UP 9 1998 17452977 WANG_CLIM2_TARGETS_DN 9 1998 17297478 VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP 4 2090 17297478 VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN 4 2090 17297478 VECCHI_GASTRIC_CANCER_EARLY_UP 4 2090 17297478 VECCHI_GASTRIC_CANCER_EARLY_DN 4 2090 17043639 BARRIER_COLON_CANCER_RECURRENCE_UP 11 2151 17043639 BARRIER_COLON_CANCER_RECURRENCE_DN 11 2151 16540638 SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP 7 2547 NaN SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP NaN NaN 17289871 JAEGER_METASTASIS_UP 35 2210 17289871 JAEGER_METASTASIS_DN 35 2210 16740760 OSMAN_BLADDER_CANCER_UP 21 2455 16740760 OSMAN_BLADDER_CANCER_DN 21 2455 16899599 GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_UP 31 2394 16899599 GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN 31 2394 16899599 GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_UP 31 2394 16899599 GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN 31 2394 16166251 OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP 11 2547 16166251 OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN 11 2547 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_LIGHTYELLOW_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_UP 60 2394 16912112 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN 60 2394 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP 20 2425 16818636 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN 20 2425 16540645 LOPEZ_MESOTELIOMA_SURVIVAL_TIME_UP 17 2547 16341039 BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_UP 4 2575 16341039 BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN 4 2575 16617321 BILBAN_B_CLL_LPL_UP 8 2455 16617321 BILBAN_B_CLL_LPL_DN 8 2455 17170726 HOEBEKE_LYMPHOID_STEM_CELL_UP 6 2210 17170726 HOEBEKE_LYMPHOID_STEM_CELL_DN 6 2210 17287849 PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP 6 2151 17287849 PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN 6 2151 17287851 AKL_HTLV1_INFECTION_UP 2 2151 17287851 AKL_HTLV1_INFECTION_DN 2 2151 17330098 RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP 1 2121 17330098 RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN 1 2121 17597811 MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP 12 1998 17597811 MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN 12 1998 17597811 MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP 12 1998 17597811 MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_DN 12 1998 17597811 MULLIGHAN_MLL_SIGNATURE_1_UP 12 1998 17597811 MULLIGHAN_MLL_SIGNATURE_1_DN 12 1998 17597811 MULLIGHAN_MLL_SIGNATURE_2_UP 12 1998 17597811 MULLIGHAN_MLL_SIGNATURE_2_DN 12 1998 17597811 MULLIGHAN_NPM1_SIGNATURE_3_UP 12 1998 17597811 MULLIGHAN_NPM1_SIGNATURE_3_DN 12 1998 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_GRANULOCYTE_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_DN 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_MONOCYTE_UP 8 1907 17898786 TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP 8 1907 16540645 LOPEZ_MESOTHELIOMA_SURVIVAL_WORST_VS_BEST_UP 17 2547 16741146 PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP 16 2394 16741146 PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN 16 2394 16551631 DITTMER_PTHLH_TARGETS_UP 5 2486 16551631 DITTMER_PTHLH_TARGETS_DN 5 2486 16574658 UDAYAKUMAR_MED1_TARGETS_UP 7 2486 16574658 UDAYAKUMAR_MED1_TARGETS_DN 7 2486 16508012 ODONNELL_TFRC_TARGETS_UP 16 2547 16508012 ODONNELL_TFRC_TARGETS_DN 16 2547 16508012 ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP 16 2547 16508012 ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN 16 2547 17470557 SENESE_HDAC1_TARGETS_UP 28 2060 17470557 SENESE_HDAC1_TARGETS_DN 28 2060 17470557 SENESE_HDAC1_AND_HDAC2_TARGETS_UP 28 2060 17470557 SENESE_HDAC1_AND_HDAC2_TARGETS_DN 28 2060 17470557 SENESE_HDAC2_TARGETS_UP 28 2060 17470557 SENESE_HDAC2_TARGETS_DN 28 2060 17470557 SENESE_HDAC3_TARGETS_UP 28 2060 17470557 SENESE_HDAC3_TARGETS_DN 28 2060 18037878 LEE_NEURAL_CREST_STEM_CELL_UP 48 1907 18037878 LEE_NEURAL_CREST_STEM_CELL_DN 48 1907 16760442 HUMMEL_BURKITTS_LYMPHOMA_UP 90 2455 16760442 HUMMEL_BURKITTS_LYMPHOMA_DN 90 2455 16394013 TIEN_INTESTINE_PROBIOTICS_2HR_UP 29 2606 16394013 TIEN_INTESTINE_PROBIOTICS_2HR_DN 29 2606 16394013 TIEN_INTESTINE_PROBIOTICS_6HR_UP 29 2606 16394013 TIEN_INTESTINE_PROBIOTICS_6HR_DN 29 2606 16394013 TIEN_INTESTINE_PROBIOTICS_24HR_UP 29 2606 16394013 TIEN_INTESTINE_PROBIOTICS_24HR_DN 29 2606 18025224 ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP 13 1907 18025224 ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN 13 1907 18025224 ZHOU_INFLAMMATORY_RESPONSE_LPS_UP 13 1907 18025224 ZHOU_INFLAMMATORY_RESPONSE_LPS_DN 13 1907 17114343 KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN 27 2302 18171984 SABATES_COLORECTAL_ADENOMA_SIZE_UP 43 1907 18171984 SABATES_COLORECTAL_ADENOMA_SIZE_DN 43 1907 18171984 SABATES_COLORECTAL_ADENOMA_UP 43 1907 18171984 SABATES_COLORECTAL_ADENOMA_DN 43 1907 17709396 SCIBETTA_KDM5B_TARGETS_UP 19 1968 17709396 SCIBETTA_KDM5B_TARGETS_DN 19 1968 17142811 NAGASHIMA_NRG1_SIGNALING_UP 17 2210 17142811 NAGASHIMA_NRG1_SIGNALING_DN 17 2210 NaN NAGASHIMA_EGF_SIGNALING_UP NaN NaN 17430890 KIM_WT1_TARGETS_UP 13 2090 17430890 KIM_WT1_TARGETS_DN 13 2090 17430890 KIM_WT1_TARGETS_8HR_UP 13 2090 17430890 KIM_WT1_TARGETS_8HR_DN 13 2090 17430890 KIM_WT1_TARGETS_12HR_UP 13 2090 17430890 KIM_WT1_TARGETS_12HR_DN 13 2090 16565084 ELVIDGE_HYPOXIA_UP 50 2455 16565084 ELVIDGE_HYPOXIA_DN 50 2455 16565084 ELVIDGE_HYPOXIA_BY_DMOG_UP 50 2455 16565084 ELVIDGE_HYPOXIA_BY_DMOG_DN 50 2455 16565084 ELVIDGE_HIF1A_TARGETS_UP 50 2455 16565084 ELVIDGE_HIF1A_TARGETS_DN 50 2455 16565084 ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP 50 2455 16565084 ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 50 2455 16210406 JAATINEN_HEMATOPOIETIC_STEM_CELL_UP 10 2547 16210406 JAATINEN_HEMATOPOIETIC_STEM_CELL_DN 10 2547 17761758 MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_UP 13 1907 17761758 MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_DN 13 1907 17717066 GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_UP 7 1907 17717066 GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_DN 7 1907 17717066 GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP 7 1907 17717066 GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN 7 1907 17717066 GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP 7 1907 17717066 GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_DN 7 1907 17717066 GRAHAM_CML_DIVIDING_VS_NORMAL_DIVIDING_UP 7 1907 17717066 GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP 7 1907 17717066 GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN 7 1907 17717066 GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP 7 1907 17717066 GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 7 1907 16397028 BIDUS_METASTASIS_UP 6 2606 16397028 BIDUS_METASTASIS_DN 6 2606 16467078 WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP 9 2575 16467078 WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN 9 2575 16467078 WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP 9 2575 16467078 WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN 9 2575 16551867 MAYBURD_RESPONSE_TO_L663536_UP 15 2547 16551867 MAYBURD_RESPONSE_TO_L663536_DN 15 2547 17255260 WATANABE_ULCERATIVE_COLITIS_WITH_CANCER_UP 8 2241 17255260 WATANABE_ULCERATIVE_COLITIS_WITH_CANCER_DN 8 2241 17406368 RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP 6 2151 17406368 RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN 6 2151 17406368 RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP 6 2151 17406368 RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN 6 2151 17406368 RODRIGUES_THYROID_CARCINOMA_UP 6 2151 17406368 RODRIGUES_THYROID_CARCINOMA_DN 6 2151 17726467 GOZGIT_ESR1_TARGETS_UP 0 1998 17726467 GOZGIT_ESR1_TARGETS_DN 0 1998 16914566 HAHTOLA_SEZARY_SYNDROM_UP 3 2394 16914566 HAHTOLA_SEZARY_SYNDROM_DN 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_DN 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_UP 3 2394 16914566 HAHTOLA_MYCOSIS_FUNGOIDES_DN 3 2394 16531451 PROVENZANI_METASTASIS_UP 21 2425 16531451 PROVENZANI_METASTASIS_DN 21 2425 NaN PACHER_TARGETS_OF_IGF1_AND_IGF2_UP NaN NaN 16990345 LIU_CDX2_TARGETS_UP 24 2210 16877703 COLDREN_GEFITINIB_RESISTANCE_UP 22 2394 16877703 COLDREN_GEFITINIB_RESISTANCE_DN 22 2394 16908595 KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP 4 2394 16908595 KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN 4 2394 16908595 KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP 4 2394 16908595 KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN 4 2394 16116475 CHOW_RASSF1_TARGETS_UP 11 2606 16116475 CHOW_RASSF1_TARGETS_DN 11 2606 16434974 ENK_UV_RESPONSE_EPIDERMIS_UP 8 2516 16434974 ENK_UV_RESPONSE_EPIDERMIS_DN 8 2516 16434974 ENK_UV_RESPONSE_KERATINOCYTE_UP 8 2516 16434974 ENK_UV_RESPONSE_KERATINOCYTE_DN 8 2516 17369842 LAU_APOPTOSIS_CDKN2A_UP 0 1998 17621275 DELYS_THYROID_CANCER_UP 7 1907 17621275 DELYS_THYROID_CANCER_DN 7 1907 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_1_UP 11 2516 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_1_DN 11 2516 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN 11 2516 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_3_UP 11 2516 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_3_DN 11 2516 16247484 KOINUMA_COLON_CANCER_MSI_DN 14 2606 17213801 CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP 12 2060 17213801 CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN 12 2060 16936776 NADERI_BREAST_CANCER_PROGNOSIS_UP 54 2182 16936776 NADERI_BREAST_CANCER_PROGNOSIS_DN 54 2182 17001317 CHIN_BREAST_CANCER_COPY_NUMBER_UP 27 2182 15940248 VANHARANTA_UTERINE_FIBROID_UP 4 2728 15940248 VANHARANTA_UTERINE_FIBROID_DN 4 2728 15940248 VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP 4 2728 15940248 VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_DN 4 2728 16983338 CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 14 2182 16983338 CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN 14 2182 15558013 ODONNELL_METASTASIS_UP 27 2940 15558013 ODONNELL_METASTASIS_DN 27 2940 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_DN 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP 4 2121 17130830 GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN 4 2121 15940270 OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP 12 2790 15940270 OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_DN 12 2790 16091735 BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_UP 16 2728 16091735 BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_DN 16 2728 16091735 BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_UP 16 2728 16091735 BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_DN 16 2728 15806164 BARIS_THYROID_CANCER_UP 6 2820 15806164 BARIS_THYROID_CANCER_DN 6 2820 16103878 TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN 6 2637 16449976 WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_UP 15 2455 16449976 WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_DN 15 2455 15940259 KERLEY_RESPONSE_TO_CISPLATIN_UP 16 2728 15637593 MISSIAGLIA_REGULATED_BY_METHYLATION_UP 7 2971 15637593 MISSIAGLIA_REGULATED_BY_METHYLATION_DN 7 2971 17533371 TANG_SENESCENCE_TP53_TARGETS_UP 3 1937 17533371 TANG_SENESCENCE_TP53_TARGETS_DN 3 1937 16449976 WANG_BARRETTS_ESOPHAGUS_UP 15 2455 16449976 WANG_BARRETTS_ESOPHAGUS_DN 15 2455 16449976 WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP 15 2455 16449976 WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN 15 2455 15735734 SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_UP 15 2881 15735734 SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN 15 2881 16702952 ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP 9 2333 16702952 ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN 9 2333 15531915 VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP 4 2971 15531915 VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN 4 2971 16652140 DUNNE_TARGETS_OF_AML1_MTG8_FUSION_UP 8 2333 16652140 DUNNE_TARGETS_OF_AML1_MTG8_FUSION_DN 8 2333 15608688 LUI_THYROID_CANCER_PAX8_PPARG_UP 8 2940 15608688 LUI_THYROID_CANCER_PAX8_PPARG_DN 8 2940 16983347 HAMAI_APOPTOSIS_VIA_TRAIL_UP 3 2272 16983347 HAMAI_APOPTOSIS_VIA_TRAIL_DN 3 2272 15940270 OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_UP 12 2790 15940270 OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_DN 12 2790 16007190 LUCAS_HNF4A_TARGETS_UP 21 2728 15897880 ZIRN_TRETINOIN_RESPONSE_WT1_UP 6 2759 15897880 ZIRN_TRETINOIN_RESPONSE_UP 6 2759 17001308 STREICHER_LSM1_TARGETS_UP 12 2182 17001308 STREICHER_LSM1_TARGETS_DN 12 2182 15592527 KAN_RESPONSE_TO_ARSENIC_TRIOXIDE 45 2940 17213809 NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP 2 2090 17213809 NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_DN 2 2090 17325667 MAHADEVAN_IMATINIB_RESISTANCE_UP 21 2090 17325667 MAHADEVAN_IMATINIB_RESISTANCE_DN 21 2090 17260014 TOMIDA_METASTASIS_UP 5 2060 17260014 TOMIDA_METASTASIS_DN 5 2060 NaN OZANNE_AP1_TARGETS_UP NaN NaN 16799640 HWANG_PROSTATE_CANCER_MARKERS 29 2241 15592519 HU_ANGIOGENESIS_UP 6 2940 15592519 HU_ANGIOGENESIS_DN 6 2940 15688035 BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP 9 2912 15688035 BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN 9 2912 16909110 OLSSON_E2F3_TARGETS_UP 12 2210 16909110 OLSSON_E2F3_TARGETS_DN 12 2210 17322921 MARKS_HDAC_TARGETS_UP 67 2210 17322921 MARKS_HDAC_TARGETS_DN 67 2210 16909099 CHOI_ATL_STAGE_PREDICTOR 9 2210 17043662 WONG_ENDMETRIUM_CANCER_UP 13 2182 17043662 WONG_ENDMETRIUM_CANCER_DN 13 2182 17001320 ABDULRAHMAN_KIDNEY_CANCER_VHL_DN 4 2182 17438526 TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA 7 1998 16862181 EGUCHI_CELL_CYCLE_RB1_TARGETS 12 2241 17404577 CHASSOT_SKIN_WOUND 8 2029 17533364 LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP 12 1937 17533364 LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN 12 1937 16909125 MUELLER_METHYLATED_IN_GLIOBLASTOMA 16 2241 17525748 EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP 8 1937 17563751 PEREZ_TP63_TARGETS 20 1937 17563751 PEREZ_TP53_AND_TP63_TARGETS 20 1937 17297437 WAKASUGI_HAVE_ZNF143_BINDING_SITES 7 2029 17334389 RODRIGUES_NTN1_AND_DCC_TARGETS 15 2029 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN 6 2940 17496919 TURJANSKI_MAPK1_AND_MAPK2_TARGETS 53 2121 17325667 MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH 21 2090 17325667 MAHADEVAN_RESPONSE_TO_MP470_DN 21 2090 17325667 MAHADEVAN_RESPONSE_TO_MP470_UP 21 2090 17213814 APPIERTO_RESPONSE_TO_FENRETINIDE_UP 2 2090 17213814 APPIERTO_RESPONSE_TO_FENRETINIDE_DN 2 2090 17694077 NAGY_TFTC_COMPONENTS_HUMAN 54 2029 16158056 SEIDEN_MET_SIGNALING 9 2606 16331256 AUNG_GASTRIC_CANCER 11 2516 16331255 SANCHEZ_MDM2_TARGETS 3 2516 16799620 BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER 43 2455 16892093 GALLUZZI_PERMEABILIZE_MITOCHONDRIA 34 2394 16998502 MATHEW_FANCONI_ANEMIA_GENES 23 2363 16785998 MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER 14 2363 17072322 SCHEIDEREIT_IKK_TARGETS 85 2333 17072329 DUTTA_APOPTOSIS_VIA_NFKB 59 2333 16247447 ROVERSI_GLIOMA_COPY_NUMBER_DN 18 2547 16158056 SEIDEN_ONCOGENESIS_BY_MET 9 2606 16314847 CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN 12 2606 16205638 KLEIN_TARGETS_OF_BCR_ABL1_FUSION 7 2575 16247447 ROVERSI_GLIOMA_LOH_REGIONS 18 2547 16247447 ROVERSI_GLIOMA_COPY_NUMBER_UP 18 2547 17486063 AIGNER_ZEB1_TARGETS 75 1968 17599052 SUZUKI_AMPLIFIED_IN_ORAL_CANCER 4 1907 17533364 LASTOWSKA_COAMPLIFIED_WITH_MYCN 12 1937 16369491 LI_LUNG_CANCER 17 2516 16369491 LI_AMPLIFIED_IN_LUNG_CANCER 17 2516 16532037 LINDGREN_BLADDER_CANCER_CLUSTER_2B 11 2516 16532037 LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE 11 2516 16532037 LINDGREN_BLADDER_CANCER_WITH_LOH_IN_CHR9Q 11 2516 16751803 MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_17 18 2302 17525748 EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_DN 8 1937 17525748 EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION 8 1937 17404570 SCHAVOLT_TARGETS_OF_TP53_AND_TP63 8 1998 16751803 MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_23 18 2302 15735737 MATTIOLI_MGUS_VS_PCL 12 2881 15735737 MATTIOLI_MGUS_VS_MULTIPLE_MYELOMA 12 2881 NaN VS NaN NaN 15897907 FARMER_BREAST_CANCER_APOCRINE_VS_BASAL 86 2790 15897907 FARMER_BREAST_CANCER_BASAL_VS_LULMINAL 86 2790 15608688 LUI_THYROID_CANCER_CLUSTER_1 8 2940 15608688 LUI_THYROID_CANCER_CLUSTER_2 8 2940 15608688 LUI_THYROID_CANCER_CLUSTER_3 8 2940 15608688 LUI_THYROID_CANCER_CLUSTER_4 8 2940 15608688 LUI_THYROID_CANCER_CLUSTER_5 8 2940 16007192 GRASEMANN_RETINOBLASTOMA_WITH_6P_AMPLIFICATION 12 2728 15608688 LUI_TARGETS_OF_PAX8_PPARG_FUSION 8 2940 15516975 SCHLOSSER_SERUM_RESPONSE_UP 12 2971 15516975 SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC 12 2971 15516975 SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 12 2971 15516975 SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM 12 2971 15516975 SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 12 2971 15516975 SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 12 2971 15516975 SCHLOSSER_SERUM_RESPONSE_DN 12 2971 15735737 MATTIOLI_MULTIPLE_MYELOMA_SUBGROUPS 12 2881 15735737 MATTIOLI_MULTIPLE_MYELOMA_WITH_14Q32_TRANSLOCATIONS 12 2881 15897907 FARMER_BREAST_CANCER_CLUSTER_1 86 2790 15897907 FARMER_BREAST_CANCER_CLUSTER_7 86 2790 15897907 FARMER_BREAST_CANCER_CLUSTER_6 86 2790 15897907 FARMER_BREAST_CANCER_CLUSTER_5 86 2790 15897907 FARMER_BREAST_CANCER_CLUSTER_4 86 2790 15897907 FARMER_BREAST_CANCER_CLUSTER_2 86 2790 16007141 ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 16 2698 17072322 SCHEIDEREIT_IKK_INTERACTING_PROTEINS 85 2333 16715129 JAERVINEN_AMPLIFIED_IN_LARYNGEAL_CANCER 11 2302 16186804 KOBAYASHI_RESPONSE_TO_ROMIDEPSIN 8 2606 16652143 PATTERSON_DOCETAXEL_RESISTANCE 14 2333 17016442 BOWIE_RESPONSE_TO_TAMOXIFEN 5 2182 17043641 AIYAR_COBRA1_TARGETS_UP 7 2151 17043641 AIYAR_COBRA1_TARGETS_DN 7 2151 17072341 LI_CISPLATIN_RESISTANCE_DN 6 2121 17072341 LI_CISPLATIN_RESISTANCE_UP 6 2121 17099727 XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR 1 2121 17099727 XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR 1 2121 17099727 XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP 1 2121 17099727 XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN 1 2121 17099727 XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_UP 1 2121 17099727 XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_DN 1 2121 17099727 XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN 1 2121 17099727 XU_AKT1_TARGETS_6HR 1 2121 17213807 SHI_SPARC_TARGETS_UP 19 2090 17213807 SHI_SPARC_TARGETS_DN 19 2090 15674343 NEBEN_AML_WITH_FLT3_OR_NRAS_DN 6 2940 15674340 DIRMEIER_LMP1_RESPONSE_EARLY 22 2912 16007187 EINAV_INTERFERON_SIGNATURE_IN_CANCER 9 2728 15824734 AMUNDSON_DNA_DAMAGE_RESPONSE_TP53 19 2820 15824737 SNIJDERS_AMPLIFIED_IN_HEAD_AND_NECK_TUMORS 43 2820 NaN WHITE_NEUROBLASTOMA_WITH_1P36.3_DELETION NaN NaN 15735734 SILIGAN_BOUND_BY_EWS_FLT1_FUSION 15 2881 15735721 DAUER_STAT3_TARGETS_UP 45 2851 15735721 DAUER_STAT3_TARGETS_DN 45 2851 15870693 KORKOLA_TERATOMA 1 2790 15870693 KORKOLA_YOLK_SAC_TUMOR 1 2790 15735726 WANG_METHYLATED_IN_BREAST_CANCER 9 2881 15688027 HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER 22 2912 15580292 SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP 2 2971 15580292 SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_DN 2 2971 15558012 MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP 26 2940 15558012 MEINHOLD_OVARIAN_CANCER_LOW_GRADE_DN 26 2940 15608684 DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_UP 6 2940 15608684 DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_DN 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_UP 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_DN 6 2940 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN 6 2940 15674340 DIRMEIER_LMP1_RESPONSE_LATE_UP 22 2912 15674340 DIRMEIER_LMP1_RESPONSE_LATE_DN 22 2912 15688027 HEIDENBLAD_AMPLICON_8Q24_UP 22 2912 15688027 HEIDENBLAD_AMPLICON_8Q24_DN 22 2912 15688027 HEIDENBLAD_AMPLICON_12P11_12_DN 22 2912 15824734 AMUNDSON_GENOTOXIC_SIGNATURE 19 2820 15824734 AMUNDSON_RESPONSE_TO_ARSENITE 19 2820 15735688 FUNG_IL2_SIGNALING_2 8 2790 NaN RUGO_ENVIRONMENTAL_STRESS_RESPONSE_UP NaN NaN 15856014 RUGO_RESPONSE_TO_4NQO 1 2790 15856014 RUGO_RESPONSE_TO_GAMMA_RADIATION 1 2790 15856014 RUGO_UV_RESPONSE 1 2790 15856014 RUGO_STRESS_RESPONSE_SUBSET_H 1 2790 15856014 RUGO_STRESS_RESPONSE_SUBSET_G 1 2790 15897875 YANAGIHARA_ESX1_TARGETS 1 2728 15897868 WEINMANN_ADAPTATION_TO_HYPOXIA_UP 5 2728 15897868 WEINMANN_ADAPTATION_TO_HYPOXIA_DN 5 2728 15608674 TSUNODA_CISPLATIN_RESISTANCE_DN 3 2940 15750621 MANN_RESPONSE_TO_AMIFOSTINE_UP 4 2820 17603561 LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP 25 1907 17603561 LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN 25 1907 17486072 WOOD_EBV_EBNA1_TARGETS_UP 13 2090 17486072 WOOD_EBV_EBNA1_TARGETS_DN 13 2090 17213808 MOHANKUMAR_TLX1_TARGETS_UP 5 2090 17213808 MOHANKUMAR_TLX1_TARGETS_DN 5 2090 17471242 DAIRKEE_TERT_TARGETS_UP 12 1998 17471242 DAIRKEE_TERT_TARGETS_DN 12 1998 17237808 MURATA_VIRULENCE_OF_H_PILORI 38 2060 17486081 WANG_HCP_PROSTATE_CANCER 22 1968 15824735 MAINA_VHL_TARGETS_DN 6 2820 15897887 GRUETZMANN_PANCREATIC_CANCER_UP 27 2790 15897887 GRUETZMANN_PANCREATIC_CANCER_DN 27 2790 15592526 JAZAG_TGFB1_SIGNALING_UP 15 2971 15592526 JAZAG_TGFB1_SIGNALING_DN 15 2971 15592526 JAZAG_TGFB1_SIGNALING_VIA_SMAD4_UP 15 2971 15592526 JAZAG_TGFB1_SIGNALING_VIA_SMAD4_DN 15 2971 16007217 SIMBULAN_UV_RESPONSE_NORMAL_DN 6 2759 16007217 SIMBULAN_UV_RESPONSE_IMMORTALIZED_DN 6 2759 16027733 WATTEL_AUTONOMOUS_THYROID_ADENOMA_UP 2 2698 16027733 WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN 2 2698 15897907 FARMER_BREAST_CANCER_CLUSTER_3 86 2790 16116477 KIM_MYC_AMPLIFICATION_TARGETS_UP 14 2606 16116477 KIM_MYC_AMPLIFICATION_TARGETS_DN 14 2606 16116477 KIM_MYCN_AMPLIFICATION_TARGETS_UP 14 2606 16116477 KIM_MYCN_AMPLIFICATION_TARGETS_DN 14 2606 16116477 KIM_MYCL1_AMPLIFICATION_TARGETS_UP 14 2606 16116477 KIM_MYCL1_AMPLIFICATION_TARGETS_DN 14 2606 16247478 TSAI_RESPONSE_TO_IONIZING_RADIATION 4 2606 16261164 YANG_BREAST_CANCER_ESR1_UP 13 2547 16261164 YANG_BREAST_CANCER_ESR1_DN 13 2547 16261164 YANG_BREAST_CANCER_ESR1_LASER_UP 13 2547 16261164 YANG_BREAST_CANCER_ESR1_LASER_DN 13 2547 16261164 YANG_BREAST_CANCER_ESR1_BULK_UP 13 2547 16261164 YANG_BREAST_CANCER_ESR1_BULK_DN 13 2547 16407838 SEMBA_FHIT_TARGETS_UP 8 2486 16205646 HASINA_NOL7_TARGETS_UP 8 2606 16205646 HASINA_NOL7_TARGETS_DN 8 2606 16407832 HATADA_METHYLATED_IN_LUNG_CANCER_UP 18 2486 16407832 HATADA_METHYLATED_IN_LUNG_CANCER_DN 18 2486 16532023 FURUKAWA_DUSP6_TARGETS_PCI35_UP 9 2394 16532023 FURUKAWA_DUSP6_TARGETS_PCI35_DN 9 2394 NaN WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP NaN NaN 16619041 KARAKAS_TGFB1_SIGNALING 5 2363 17603561 LIEN_BREAST_CARCINOMA_METAPLASTIC 25 1907 17173048 TOMLINS_PROSTATE_CANCER_UP 135 2241 17173048 TOMLINS_PROSTATE_CANCER_DN 135 2241 17173048 TOMLINS_METASTASIS_UP 135 2241 17173048 TOMLINS_METASTASIS_DN 135 2241 17206142 SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP 129 2210 17206142 SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_DN 129 2210 17206142 SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP 129 2210 17206142 SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN 129 2210 17704777 BALLIF_DEVELOPMENTAL_DISABILITY_P16_P12_DELETION 31 1998 17922014 PUJANA_BREAST_CANCER_LIT_INT_NETWORK 88 1937 17922014 PUJANA_XPRSS_INT_NETWORK 88 1937 17922014 PUJANA_BRCA2_PCC_NETWORK 88 1937 17922014 PUJANA_CHEK2_PCC_NETWORK 88 1937 17922014 PUJANA_BRCA_CENTERED_NETWORK 88 1937 17200670 SCHLESINGER_H3K27ME3_IN_NORMAL_AND_METHYLATED_IN_CANCER 184 2210 17200670 SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER 184 2210 17873875 GOERING_BLOOD_HDL_CHOLESTEROL_QTL_CIS 150 1968 17211412 OHM_METHYLATED_IN_ADULT_CANCERS 177 2210 17621274 ALCALA_APOPTOSIS 14 1876 17667943 OKAWA_NEUROBLASTOMA_1P36_31_DELETION 16 1876 17704800 COWLING_MYCN_TARGETS 2 1845 17724461 FALVELLA_SMOKERS_WITH_LUNG_CANCER 2 1816 17891175 OZEN_MIR125B1_TARGETS 85 1816 17891185 KAUFFMANN_MELANOMA_RELAPSE_UP 19 1876 17700529 WILLIAMS_ESR1_TARGETS_UP 16 1845 17700529 WILLIAMS_ESR2_TARGETS_UP 16 1845 17724462 NUYTTEN_NIPP1_TARGETS_UP 7 1845 17724462 NUYTTEN_NIPP1_TARGETS_DN 7 1845 17724462 NUYTTEN_EZH2_TARGETS_UP 7 1845 17724462 NUYTTEN_EZH2_TARGETS_DN 7 1845 17952126 BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP 11 1816 17952126 BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN 11 1816 17952124 FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP 10 1816 17952124 FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN 10 1816 18071306 NAKAYAMA_FRA2_TARGETS 4 1755 18223687 LOPEZ_MBD_TARGETS 7 1724 18223687 LOPEZ_MBD_TARGETS_IMPRINTED_AND_X_LINKED 7 1724 18264134 ROPERO_HDAC2_TARGETS 6 1724 18332864 LIU_LIVER_CANCER 0 1694 18332864 LIU_BREAST_CANCER 0 1694 18332864 LIU_NASOPHARYNGEAL_CARCINOMA 0 1694 18332864 LIU_COMMON_CANCER_GENES 0 1694 18391978 LOCKWOOD_AMPLIFIED_IN_LUNG_CANCER 26 1694 18504438 WEI_MIR34A_TARGETS 50 1632 18504438 WEI_MYCN_TARGETS_WITH_E_BOX 50 1632 18504433 LIAO_HAVE_SOX4_BINDING_SITES 16 1632 18504433 LIAO_METASTASIS 16 1632 18663361 TONG_INTERACT_WITH_PTTG1 5 1602 17982488 SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN 10 1785 17982488 SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_DN 10 1785 18037961 GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP 38 1755 18037961 GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_DN 38 1755 18026132 SCHWAB_TARGETS_OF_BMYB_S427G_UP 2 1755 18026132 SCHWAB_TARGETS_OF_BMYB_S427G_DN 2 1755 18026132 SCHWAB_TARGETS_OF_BMYB_I624M_UP 2 1755 18026132 SCHWAB_TARGETS_OF_BMYB_I624M_DN 2 1755 18317448 GOUYER_TATI_TARGETS_DN 10 1694 18454173 CAFFAREL_RESPONSE_TO_THC_UP 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_DN 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_8HR_5_UP 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_8HR_5_DN 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_24HR_3_DN 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_24HR_5_UP 4 1663 18454173 CAFFAREL_RESPONSE_TO_THC_24HR_5_DN 4 1663 18490921 BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_UP 13 1632 18490921 BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN 13 1632 NaN SUH_COEXPRESSED_WITH_ID1_AND_ID2_UP NaN NaN 18591936 GARCIA_TARGETS_OF_FLI1_AND_DAX1_UP 17 1602 18591936 GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN 17 1602 18679425 RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP 10 1571 18679425 RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN 10 1571 18679425 RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_UP 10 1571 18679425 RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN 10 1571 18679425 RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP 10 1571 18679425 RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN 10 1571 18679425 RICKMAN_METASTASIS_UP 10 1571 18679425 RICKMAN_METASTASIS_DN 10 1571 18711403 FRIDMAN_SENESCENCE_UP 22 1602 18711403 FRIDMAN_SENESCENCE_DN 22 1602 18711403 FRIDMAN_IMMORTALIZATION_DN 22 1602 18985860 KOYAMA_SEMA3B_TARGETS_UP 2 1571 18985860 KOYAMA_SEMA3B_TARGETS_DN 2 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_A 10 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_B 10 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_C 10 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_D 10 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_E 10 1571 18679425 RICKMAN_HEAD_AND_NECK_CANCER_F 10 1571 18724390 WU_CELL_MIGRATION 9 1571 18762810 TAGHAVI_NEOPLASTIC_TRANSFORMATION 10 1571 16314830 COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_UP 6 2486 16314830 COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN 6 2486 NaN BALDWIN_PRKCI_TARGETS_UP NaN NaN 17322878 AMIT_DELAYED_EARLY_GENES 58 2151 18443585 BENPORATH_ES_1 261 1755 18443585 BENPORATH_ES_2 261 1755 18443585 BENPORATH_NANOG_TARGETS 261 1755 18443585 BENPORATH_OCT4_TARGETS 261 1755 18443585 BENPORATH_SOX2_TARGETS 261 1755 18443585 BENPORATH_NOS_TARGETS 261 1755 18443585 BENPORATH_PRC2_TARGETS 261 1755 18443585 BENPORATH_MYC_TARGETS_WITH_EBOX 261 1755 18443585 BENPORATH_MYC_MAX_TARGETS 261 1755 18443585 BENPORATH_CYCLING_GENES 261 1755 18443585 BENPORATH_PROLIFERATION 261 1755 18443592 PETRETTO_CARDIAC_HYPERTROPHY 17 1755 18443585 BENPORATH_ES_CORE_NINE_CORRELATED 261 1755 17322878 AMIT_EGF_RESPONSE_20_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_40_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_60_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_120_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_240_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_480_HELA 58 2151 17322878 AMIT_EGF_RESPONSE_20_MCF10A 58 2151 17322878 AMIT_EGF_RESPONSE_40_MCF10A 58 2151 17322878 AMIT_EGF_RESPONSE_60_MCF10A 58 2151 17322878 AMIT_EGF_RESPONSE_120_MCF10A 58 2151 17322878 AMIT_EGF_RESPONSE_240_MCF10A 58 2151 17322878 AMIT_EGF_RESPONSE_480_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_20_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_40_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_60_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_120_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_240_MCF10A 58 2151 17322878 AMIT_SERUM_RESPONSE_480_MCF10A 58 2151 19074876 GEORGES_CELL_CYCLE_MIR192_TARGETS 45 1541 19074876 GEORGES_TARGETS_OF_MIR192_AND_MIR215 45 1541 19074882 SHEN_SMARCA2_TARGETS_UP 8 1541 19074882 SHEN_SMARCA2_TARGETS_DN 8 1541 19074894 LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT 16 1541 19074895 SAKAI_TUMOR_INFILTRATING_MONOCYTES_DN 3 1541 19074895 SAKAI_TUMOR_INFILTRATING_MONOCYTES_UP 3 1541 19074895 SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN 3 1541 19047146 JEON_SMAD6_TARGETS_UP 6 1541 19047146 JEON_SMAD6_TARGETS_DN 6 1541 19047173 WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT 24 1541 19047182 SUNG_METASTASIS_STROMA_UP 22 1541 19047182 SUNG_METASTASIS_STROMA_DN 22 1541 19010928 ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 5 1571 19010928 ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN 5 1571 15592499 COLLIS_PRKDC_SUBSTRATES 62 2940 15592499 COLLIS_PRKDC_REGULATORS 62 2940 17891185 KAUFFMANN_DNA_REPAIR_GENES 19 1876 17891185 KAUFFMANN_DNA_REPLICATION_GENES 19 1876 19010930 NIKOLSKY_BREAST_CANCER_1Q21_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_1Q32_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_5P15_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_6P24_P22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_7P22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_7P15_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_12Q24_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_14Q22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_16P13_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON 15 1571 NaN NIKOLSKY_BREAST_CANCER_19Q13.1_AMPLICON NaN NaN 19010930 NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON 15 1571 19010930 NIKOLSKY_BREAST_CANCER_22Q13_AMPLICON 15 1571 19010930 NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER 15 1571 17429401 WHITEHURST_PACLITAXEL_SENSITIVITY 75 2151 NaN STEGMEIER_PRE-MITOTIC_CELL_CYCLE_REGULATORS NaN NaN 17676035 JI_METASTASIS_REPRESSED_BY_STK11 96 2029 18075594 GOTTWEIN_TARGETS_OF_KSHV_MIR_K12_11 121 1907 18923524 CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS 59 1602 18772890 TCGA_GLIOBLASTOMA_COPY_NUMBER_UP 657 1602 18772890 TCGA_GLIOBLASTOMA_COPY_NUMBER_DN 657 1602 18948947 DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY 285 1602 18948947 DING_LUNG_CANCER_MUTATED_FREQUENTLY 285 1602 18948947 DING_LUNG_CANCER_EXPRESSION_BY_COPY_NUMBER 285 1602 18483246 ONDER_CDH1_TARGETS_2_UP 93 1755 18483246 ONDER_CDH1_TARGETS_2_DN 93 1755 18483246 ONDER_CDH1_TARGETS_1_UP 93 1755 18483246 ONDER_CDH1_TARGETS_1_DN 93 1755 18483246 ONDER_CDH1_TARGETS_3_UP 93 1755 18483246 ONDER_CDH1_TARGETS_3_DN 93 1755 18483246 ONDER_CDH1_SIGNALING_VIA_CTNNB1 93 1755 18519664 CERVERA_SDHB_TARGETS_2 11 1724 18519667 ROZANOV_MMP14_TARGETS_SUBSET 13 1724 18519667 ROZANOV_MMP14_CORRELATED 13 1724 18519667 ROZANOV_MMP14_TARGETS_UP 13 1724 18519667 ROZANOV_MMP14_TARGETS_DN 13 1724 18676831 LANDEMAINE_LUNG_METASTASIS 16 1663 18519664 CERVERA_SDHB_TARGETS_1_UP 11 1724 18519664 CERVERA_SDHB_TARGETS_1_DN 11 1724 15226186 ROSS_ACUTE_MYELOID_LEUKEMIA_CBF 66 3002 15642117 KENNY_CTNNB1_TARGETS_UP 6 2971 12704389 CHEOK_RESPONSE_TO_MERCAPTOPURINE_DN 31 3582 12185249 NELSON_RESPONSE_TO_ANDROGEN_DN 63 3824 12663452 TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_UP 29 3521 15608639 SWEET_KRAS_TARGETS_DN 98 2971 16150706 SHEPARD_CRUSH_AND_BURN_MUTANT_UP 36 2728 15226186 ROSS_AML_WITH_PML_RARA_FUSION 66 3002 15565109 LEE_LIVER_CANCER_CIPROFIBRATE_DN 70 3002 15303102 ASTON_MAJOR_DEPRESSIVE_DISORDER_DN 45 2912 11937641 STANELLE_E2F1_TARGETS 31 3977 11786909 SHIPP_DLBCL_CURED_VS_FATAL_DN 199 4067 11991981 GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3 114 3916 10521349 GOLUB_ALL_VS_AML_UP 997 4890 15778709 BASSO_B_LYMPHOCYTE_NETWORK 216 2881 15226186 ROSS_AML_WITH_CBFB_MYH11_FUSION 66 3002 15710396 IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_UP 2 2940 12086890 FERRANDO_TAL1_NEIGHBORS 110 4036 12101249 PENG_LEUCINE_DEPRIVATION_UP 59 3855 15565109 LEE_LIVER_CANCER_MYC_TGFA_DN 70 3002 15710396 IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_DN 2 2940 12914697 LAMB_CCND1_TARGETS 97 3490 12433680 GNATENKO_PLATELET_SIGNATURE 52 3643 16150706 SHEPARD_BMYB_MORPHOLINO_DN 36 2728 15565109 LEE_LIVER_CANCER_ACOX1_DN 70 3002 12717449 SMITH_TERT_TARGETS_UP 55 3582 15565109 LEE_LIVER_CANCER_MYC_UP 70 3002 11983916 MENSSEN_MYC_TARGETS 76 3977 15710396 IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_DN 2 2940 9861020 DER_IFN_ALPHA_RESPONSE_UP 333 5194 11402317 KANNAN_TP53_TARGETS_UP 55 4342 14973112 FRASOR_RESPONSE_TO_ESTRADIOL_UP 66 3306 15565109 LEE_LIVER_CANCER_MYC_TGFA_UP 70 3002 15307835 FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN 32 3093 14604967 DORSAM_HOXA9_TARGETS_UP 20 3277 15710396 IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_UP 2 2940 12531789 KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN 30 3582 16150706 SHEPARD_BMYB_TARGETS 36 2728 11402317 KANNAN_TP53_TARGETS_DN 55 4342 18676852 CHANG_POU5F1_TARGETS_UP 9 1663 15749026 SANA_TNF_SIGNALING_DN 16 2912 12663452 TARTE_PLASMA_CELL_VS_PLASMABLAST_UP 29 3521 12095419 WILLERT_WNT_SIGNALING 69 3886 12101249 PENG_LEUCINE_DEPRIVATION_DN 59 3855 15642117 KENNY_CTNNB1_TARGETS_DN 6 2971 15657362 BECKER_TAMOXIFEN_RESISTANCE_UP 18 2971 16150706 SHEPARD_CRUSH_AND_BURN_MUTANT_DN 36 2728 11910354 RADAEVA_RESPONSE_TO_IFNA1_UP 25 3977 12663452 TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN 29 3521 15447987 KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_DN 7 3093 12738660 YAGI_AML_RELAPSE_PROGNOSIS 20 3459 11786909 SHIPP_DLBCL_CURED_VS_FATAL_UP 199 4067 15307835 FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 32 3093 15565109 LEE_LIVER_CANCER_ACOX1_UP 70 3002 12704389 CHEOK_RESPONSE_TO_MERCAPTOPURINE_UP 31 3582 14573703 CHEN_LUNG_CANCER_SURVIVAL 24 3398 11807556 POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP 231 4067 NaN WIELAND_UP_BY_HBV_INFECTION NaN NaN 16150706 SHEPARD_BMYB_MORPHOLINO_UP 36 2728 10521349 GOLUB_ALL_VS_AML_DN 997 4890 9861020 DER_IFN_BETA_RESPONSE_UP 333 5194 15374877 MANALO_HYPOXIA_DN 108 2971 15565109 LEE_LIVER_CANCER_MYC_E2F1_DN 70 3002 12185249 NELSON_RESPONSE_TO_ANDROGEN_UP 63 3824 11522623 LIN_APC_TARGETS 8 4189 11823860 VANTVEER_BREAST_CANCER_METASTASIS_DN 1182 4067 12969979 BROCKE_APOPTOSIS_REVERSED_BY_IL6 12 3337 11807556 POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN 231 4067 14973112 FRASOR_RESPONSE_TO_ESTRADIOL_DN 66 3306 12704389 CHEOK_RESPONSE_TO_HD_MTX_DN 31 3582 15271793 TENEDINI_MEGAKARYOCYTE_MARKERS 12 3032 12663452 TARTE_PLASMA_CELL_VS_PLASMABLAST_DN 29 3521 12591738 SMITH_LIVER_CANCER 21 3671 15226186 ROSS_AML_WITH_MLL_FUSIONS 66 3002 15565109 LEE_LIVER_CANCER_MYC_E2F1_UP 70 3002 15303102 ASTON_MAJOR_DEPRESSIVE_DISORDER_UP 45 2912 12695333 FERNANDEZ_BOUND_BY_MYC 178 3582 15307835 FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP 32 3093 15226186 ROSS_AML_OF_FAB_M7_TYPE 66 3002 12808457 MOOTHA_VOXPHOS 713 3521 15307835 FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN 32 3093 15749026 SANA_RESPONSE_TO_IFNG_UP 16 2912 15749026 SANA_TNF_SIGNALING_UP 16 2912 11807556 POMEROY_MEDULLOBLASTOMA_PROGNOSIS_UP 231 4067 11139609 SCHUHMACHER_MYC_TARGETS_UP 62 4432 15608639 SWEET_KRAS_TARGETS_UP 98 2971 12704389 CHEOK_RESPONSE_TO_HD_MTX_UP 31 3582 12855579 OKUMURA_INFLAMMATORY_RESPONSE_LPS 16 3429 12717449 SMITH_TERT_TARGETS_DN 55 3582 11786909 SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN 199 4067 15565109 LEE_LIVER_CANCER_DENA_DN 70 3002 15749026 SANA_RESPONSE_TO_IFNG_DN 16 2912 12704389 CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_LD_MTX_DN 31 3582 15565109 LEE_LIVER_CANCER_MYC_DN 70 3002 15565109 LEE_LIVER_CANCER_CIPROFIBRATE_UP 70 3002 15710396 IIZUKA_LIVER_CANCER_PROGRESSION_L1_G1_UP 2 2940 11807556 POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN 231 4067 15591113 LU_IL4_SIGNALING 19 2881 12086890 FERRANDO_LYL1_NEIGHBORS 110 4036 11823860 VANTVEER_BREAST_CANCER_METASTASIS_UP 1182 4067 10737792 COLLER_MYC_TARGETS_UP 149 4738 15374877 MANALO_HYPOXIA_UP 108 2971 11799067 REN_BOUND_BY_E2F 246 4067 15709204 WONG_IFNA2_RESISTANCE_DN 1 2940 14604967 DORSAM_HOXA9_TARGETS_DN 20 3277 15307835 FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN 32 3093 11786909 SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP 199 4067 15657362 BECKER_TAMOXIFEN_RESISTANCE_DN 18 2971 12531789 KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP 30 3582 15471956 SASAKI_ADULT_T_CELL_LEUKEMIA 15 2940 12101249 PENG_RAPAMYCIN_RESPONSE_DN 59 3855 15565109 LEE_LIVER_CANCER_E2F1_DN 70 3002 15565109 LEE_LIVER_CANCER_DENA_UP 70 3002 15307835 FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN 32 3093 12101249 PENG_RAPAMYCIN_RESPONSE_UP 59 3855 12101249 PENG_GLUTAMINE_DEPRIVATION_DN 59 3855 15307835 FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 32 3093 15307835 FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP 32 3093 15565109 LEE_LIVER_CANCER_E2F1_UP 70 3002 15226186 ROSS_AML_WITH_AML1_ETO_FUSION 66 3002 15070671 BHATTACHARYA_EMBRYONIC_STEM_CELL 49 3246 9861020 DER_IFN_GAMMA_RESPONSE_UP 333 5194 15459216 HASLINGER_B_CLL_WITH_17P13_DELETION 25 3063 11493461 NAKAJIMA_EOSINOPHIL 9 4220 15252187 ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN 11 3093 11861292 ZHAN_MULTIPLE_MYELOMA_SUBGROUPS 83 4008 15331438 HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP 15 3002 15459216 HASLINGER_B_CLL_WITH_MUTATED_VH_GENES 25 3063 14676830 CROMER_METASTASIS_UP 34 3246 15831697 ALCALAY_AML_BY_NPM1_LOCALIZATION_UP 26 2759 15817677 FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP 4 2790 16140955 XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP 1 2728 15033914 STOSSI_RESPONSE_TO_ESTRADIOL 45 3155 15827134 MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_DN 42 2759 12637319 FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP 40 3521 11468180 HOFMANN_CELL_LYMPHOMA_DN 21 4220 15459216 HASLINGER_B_CLL_WITH_13Q14_DELETION 25 3063 11468180 HOFMANN_CELL_LYMPHOMA_UP 21 4220 11773596 HSIAO_LIVER_SPECIFIC_GENES 83 4098 12438227 GILDEA_METASTASIS 29 3763 11861292 ZHAN_MULTIPLE_MYELOMA_SPIKED 83 4008 12393420 ASTIER_INTEGRIN_SIGNALING 0 3671 15459216 HASLINGER_B_CLL_WITH_11Q23_DELETION 25 3063 15105423 LEI_MYB_TARGETS 13 3155 12057921 LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN 33 3916 15205324 HALMOS_CEBPA_TARGETS_DN 11 3185 12637319 FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN 40 3521 16105978 GALE_APL_WITH_FLT3_MUTATED_DN 19 2637 14973077 RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP 9 3306 15205324 HALMOS_CEBPA_TARGETS_UP 11 3185 11861292 ZHAN_MULTIPLE_MYELOMA_UP 83 4008 11279020 LENAOUR_DENDRITIC_CELL_MATURATION_UP 37 4312 14517214 TAVOR_CEBPA_TARGETS_DN 15 3368 11279020 LENAOUR_DENDRITIC_CELL_MATURATION_DN 37 4312 15331438 HADDAD_B_LYMPHOCYTE_PROGENITOR 15 3002 16618808 NGUYEN_NOTCH1_TARGETS_UP 63 2516 15459216 HASLINGER_B_CLL_WITH_CHROMOSOME_12_TRISOMY 25 3063 15388584 ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP 3 2971 15187151 THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP 21 3185 16109776 VERHAAK_AML_WITH_NPM1_MUTATED_UP 43 2637 15579653 KANG_IMMORTALIZED_BY_TERT_UP 3 NaN 15331443 BASSO_CD40_SIGNALING_DN 21 3002 15578091 JAIN_NFKB_SIGNALING 20 3002 12057921 LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP 33 3916 16105978 GALE_APL_WITH_FLT3_MUTATED_UP 19 2637 15187151 THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN 21 3185 15817677 FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN 4 2790 12923195 VERNELL_RETINOBLASTOMA_PATHWAY_UP 34 3398 15831697 ALCALAY_AML_BY_NPM1_LOCALIZATION_DN 26 2759 15579653 KANG_IMMORTALIZED_BY_TERT_DN 3 NaN 16618808 NGUYEN_NOTCH1_TARGETS_DN 63 2516 15827134 MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP 42 2759 16160012 CHIARETTI_ACUTE_LYMPHOBLASTIC_LEUKEMIA_ZAP70 2 2606 12411303 HOEGERKORP_CD44_TARGETS_DIRECT_DN 4 3643 12642603 BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS 237 3643 16140955 XU_RESPONSE_TO_TRETINOIN_UP 1 2728 15388584 ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_DN 3 2971 NaN MENSE_HYPOXIA_UP NaN NaN 12393520 ZHAN_V2_LATE_DIFFERENTIATION_GENES 22 3671 11830491 DORSEY_GAB2_TARGETS 12 4036 15331438 HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN 15 3002 11493461 NAKAJIMA_MAST_CELL 9 4220 16670265 RADMACHER_AML_PROGNOSIS 21 2363 14676830 CROMER_METASTASIS_DN 34 3246 15302897 NOUZOVA_METHYLATED_IN_APL 19 3002 14517214 TAVOR_CEBPA_TARGETS_UP 15 3368 12738660 YAGI_AML_SURVIVAL 20 3459 16109776 VERHAAK_AML_WITH_NPM1_MUTATED_DN 43 2637 14973077 RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_DN 9 3306 15756019 APPEL_IMATINIB_RESPONSE 10 2912 12738660 YAGI_AML_FAB_MARKERS 20 3459 15827134 MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN 42 2759 12411303 HOEGERKORP_CD44_TARGETS_TEMPORAL_DN 4 3643 12969976 MUNSHI_MULTIPLE_MYELOMA_UP 19 3277 11861292 ZHAN_MULTIPLE_MYELOMA_DN 83 4008 15331443 BASSO_CD40_SIGNALING_UP 21 3002 15817677 FAELT_B_CLL_WITH_VH3_21_DN 4 2790 16140955 XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DN 1 2728 15302897 NOUZOVA_TRETINOIN_AND_H4_ACETYLATION 19 3002 15827134 MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_UP 42 2759 12411303 HOEGERKORP_CD44_TARGETS_DIRECT_UP 4 3643 15817677 FAELT_B_CLL_WITH_VH3_21_UP 4 2790 18701482 REN_ALVEOLAR_RHABDOMYOSARCOMA_UP 15 1663 18701482 REN_ALVEOLAR_RHABDOMYOSARCOMA_DN 15 1663 11487589 GEISS_RESPONSE_TO_DSRNA_DN 52 4220 14734480 KANG_FLUOROURACIL_RESISTANCE_DN 18 3337 14734480 KANG_FLUOROURACIL_RESISTANCE_UP 18 3337 14734480 KANG_DOXORUBICIN_RESISTANCE_UP 18 3337 14734480 KANG_DOXORUBICIN_RESISTANCE_DN 18 3337 12032322 WELCSH_BRCA1_TARGETS_1_UP 34 3947 11487589 GEISS_RESPONSE_TO_DSRNA_UP 52 4220 11313881 KALMA_E2F1_TARGETS 16 4373 12032322 WELCSH_BRCA1_TARGETS_1_DN 34 3947 16273092 BILD_MYC_ONCOGENIC_SIGNATURE 365 2606 16273092 BILD_E2F3_ONCOGENIC_SIGNATURE 365 2606 16273092 BILD_HRAS_ONCOGENIC_SIGNATURE 365 2606 16273092 BILD_SRC_ONCOGENIC_SIGNATURE 365 2606 16273092 BILD_CTNNB1_ONCOGENIC_SIGNATURE 365 2606 18701473 DOUGLAS_BMI1_TARGETS_UP 17 1663 18701473 DOUGLAS_BMI1_TARGETS_DN 17 1663 18701491 KRIGE_AMINO_ACID_DEPRIVATION 4 1663 18701491 KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP 4 1663 18701491 KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN 4 1663 18701491 KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 4 1663 18701491 KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_DN 4 1663 18701499 GHO_ATF5_TARGETS_DN 4 1663 18757419 LI_CYTIDINE_ANALOGS_CYCTOTOXICITY 36 1632 18757419 LI_CYTIDINE_ANALOG_PATHWAY 36 1632 18757430 KIM_LRRC3B_TARGETS 0 1632 18794137 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1 15 1632 18794137 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2 15 1632 18794137 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3 15 1632 18794137 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4 15 1632 18794137 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5 15 1632 18829555 SINGH_NFE2L2_TARGETS 36 1602 18829567 PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP 2 1602 18829567 PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_DN 2 1602 18794111 LOPES_METHYLATED_IN_COLON_CANCER_UP 15 1632 18794111 LOPES_METHYLATED_IN_COLON_CANCER_DN 15 1632 15608684 DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP 6 2940 18974140 YEGNASUBRAMANIAN_PROSTATE_CANCER 26 1571 18974135 RIGGINS_TAMOXIFEN_RESISTANCE_UP 9 1571 18974135 RIGGINS_TAMOXIFEN_RESISTANCE_DN 9 1571 19010930 NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER 15 1571 18974123 STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP 18 1571 18974123 STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN 18 1571 18974123 STEIN_ESRRA_TARGETS_UP 18 1571 18974123 STEIN_ESRRA_TARGETS_DN 18 1571 15897889 KYNG_DNA_DAMAGE_BY_4NQO 5 2790 15897889 KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION 5 2790 15897889 KYNG_DNA_DAMAGE_BY_UV 5 2790 15897889 KYNG_DNA_DAMAGE_BY_4NQO_OR_UV 5 2790 15897889 KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION 5 2790 15897889 KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_4NQO_IN_WS 5 2790 15897889 KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_OLD 5 2790 15897889 KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS 5 2790 15897889 KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_UV_IN_OLD 5 2790 15897889 KYNG_DNA_DAMAGE_UP 5 2790 15897889 KYNG_DNA_DAMAGE_DN 5 2790 NaN KYNG_ENVIRONMENTAL_STRESS_RESPONSE_UP NaN NaN 18488029 KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3 114 1724 18488029 KONDO_PROSTATE_CANCER_WITH_H3K27ME3 114 1724 18488029 KONDO_COLON_CANCER_HCP_WITH_H3K27ME1 114 1724 18488029 KONDO_EZH2_TARGETS 114 1724 18519680 LEE_LIVER_CANCER 8 1724 14734480 KANG_CISPLATIN_RESISTANCE_UP 18 3337 18172295 HELLER_SILENCED_BY_METHYLATION_UP 13 1876 18172295 HELLER_SILENCED_BY_METHYLATION_DN 13 1876 18172295 HELLER_HDAC_TARGETS_UP 13 1876 18172295 HELLER_HDAC_TARGETS_DN 13 1876 18172295 HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP 13 1876 18172295 HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN 13 1876 18172325 CLAUS_PGR_POSITIVE_MENINGIOMA_DN 5 1876 18199530 WONG_MITOCHONDRIA_GENE_MODULE 12 1876 18199530 WONG_PROTEASOME_GENE_MODULE 12 1876 18199535 AMUNDSON_GAMMA_RADIATION_RESISTANCE 34 1876 18199535 AMUNDSON_GAMMA_RADIATION_RESPONSE 34 1876 18199535 AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_8G 34 1876 18199535 AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_2G 34 1876 NaN LEE_METASTASIS_AND_RNA_PROCESSING_UP NaN NaN 18245461 LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_UP 7 1845 18245461 LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_DN 7 1845 18245465 LIN_MELANOMA_COPY_NUMBER_UP 47 1845 18245465 LIN_MELANOMA_COPY_NUMBER_DN 47 1845 18245477 FINETTI_BREAST_CANCER_KINOME_RED 11 1845 18245477 FINETTI_BREAST_CANCER_KINOME_GREEN 11 1845 18245477 FINETTI_BREAST_CANCERS_KINOME_BLUE 11 1845 18245477 FINETTI_BREAST_CANCERS_KINOME_GRAY 11 1845 18245477 FINETTI_BREAST_CANCER_BASAL_VS_LUMINAL 11 1845 18245484 MASSARWEH_TAMOXIFEN_RESISTANCE_UP 49 1845 18245484 MASSARWEH_TAMOXIFEN_RESISTANCE_DN 49 1845 18245484 MASSARWEH_RESPONSE_TO_ESTRADIOL 49 1845 18245496 WALLACE_PROSTATE_CANCER_UP 35 1845 18245496 WALLACE_PROSTATE_CANCER_RACE_UP 35 1845 18245496 WALLACE_PROSTATE_CANCER_RACE_DN 35 1845 18281472 SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP 94 1845 18281475 OUILLETTE_CLL_13Q14_DELETION_UP 22 1845 18281475 OUILLETTE_CLL_13Q14_DELETION_DN 22 1845 18281482 YOKOE_CANCER_TESTIS_ANTIGENS 3 1845 18281483 MARZEC_IL2_SIGNALING_UP 9 1845 18281483 MARZEC_IL2_SIGNALING_DN 9 1845 18316590 CAMPS_COLON_CANCER_COPY_NUMBER_UP 21 1816 18316590 CAMPS_COLON_CANCER_COPY_NUMBER_DN 21 1816 18316601 RIZKI_TUMOR_INVASIVENESS_3D_UP 25 1816 18316601 RIZKI_TUMOR_INVASIVENESS_3D_DN 25 1816 18316601 RIZKI_TUMOR_INVASIVENESS_2D_UP 25 1816 18316601 RIZKI_TUMOR_INVASIVENESS_2D_DN 25 1816 18316615 FUJII_YBX1_TARGETS_UP 7 1816 18316615 FUJII_YBX1_TARGETS_DN 7 1816 18339843 OSADA_ASCL1_TARGETS_UP 11 1816 18339843 OSADA_ASCL1_TARGETS_DN 11 1816 18339859 CHENG_IMPRINTED_BY_ESTRADIOL 28 1816 18339860 DE_YY1_TARGETS_UP 8 1816 18339860 DE_YY1_TARGETS_DN 8 1816 18339881 MCCABE_BOUND_BY_HOXC6 11 1816 18381411 DAIRKEE_CANCER_PRONE_RESPONSE_E2 18 1785 18381411 DAIRKEE_CANCER_PRONE_RESPONSE_BPA 18 1785 18381411 DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 18 1785 18381423 RIGGI_EWING_SARCOMA_PROGENITOR_UP 38 1785 18381423 RIGGI_EWING_SARCOMA_PROGENITOR_DN 38 1785 18381434 VICENT_METASTASIS_UP 5 1785 18381438 AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53 9 1785 18381439 HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP 21 1785 18381439 HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN 21 1785 18381450 ENGELMANN_CANCER_PROGENITORS_UP 18 1785 18381450 ENGELMANN_CANCER_PROGENITORS_DN 18 1785 18593902 HUANG_FOXA2_TARGETS_UP 6 1694 18593902 HUANG_FOXA2_TARGETS_DN 6 1694 18559539 MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_UP 20 1724 18559539 MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN 20 1724 18519693 MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_UP 72 1724 18339881 MCCABE_HOXC6_TARGETS_DN 11 1816 18413723 TING_SILENCED_BY_DICER 8 1785 18339881 MCCABE_HOXC6_TARGETS_CANCER_UP 11 1816 18339881 MCCABE_HOXC6_TARGETS_CANCER_DN 11 1816 18413728 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP 14 1785 18413728 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 14 1785 18413731 ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP 10 1785 18413731 ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN 10 1785 18413731 ACEVEDO_LIVER_CANCER_UP 10 1785 18413731 ACEVEDO_LIVER_CANCER_DN 10 1785 18413731 ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_UP 10 1785 18413731 ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN 10 1785 18413731 ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP 10 1785 18413731 ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN 10 1785 18413731 ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_UP 10 1785 18413731 ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_DN 10 1785 18413731 ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN 10 1785 18593922 MITSIADES_RESPONSE_TO_APLIDIN_UP 9 1694 18593922 MITSIADES_RESPONSE_TO_APLIDIN_DN 9 1694 18413733 HOQUE_METHYLATED_IN_CANCER 29 1785 18413748 SAGIV_CD24_TARGETS_UP 8 1785 18413748 SAGIV_CD24_TARGETS_DN 8 1785 18451135 SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_LUNG_UP 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN 54 1755 18451135 SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_DN 54 1755 18451135 SMID_BREAST_CANCER_LUMINAL_B_UP 54 1755 18451135 SMID_BREAST_CANCER_LUMINAL_B_DN 54 1755 18451135 SMID_BREAST_CANCER_LUMINAL_A_UP 54 1755 18451135 SMID_BREAST_CANCER_LUMINAL_A_DN 54 1755 18451135 SMID_BREAST_CANCER_ERBB2_UP 54 1755 18451135 SMID_BREAST_CANCER_NORMAL_LIKE_UP 54 1755 18451135 SMID_BREAST_CANCER_BASAL_UP 54 1755 18451135 SMID_BREAST_CANCER_BASAL_DN 54 1755 18451147 ITO_PTTG1_TARGETS_UP 5 1755 18451154 LE_SKI_TARGETS_UP 19 1755 18593951 BONOME_OVARIAN_CANCER_POOR_SURVIVAL_UP 16 1694 18593951 BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN 16 1694 18593951 BONOME_OVARIAN_CANCER_SURVIVAL_OPTIMAL_DEBULKING 16 1694 18593951 BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING 16 1694 18632618 MOSERLE_IFNA_RESPONSE 10 1694 18632628 MCGARVEY_SILENCED_BY_METHYLATION_IN_COLON_CANCER 27 1694 17334365 WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN 335 2151 17334365 WEBER_METHYLATED_HCP_IN_SPERM_DN 335 2151 17334365 WEBER_METHYLATED_HCP_IN_SPERM_UP 335 2151 14707115 BASSO_HAIRY_CELL_LEUKEMIA_DN 6 3337 18519671 TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C 60 1724 18519680 LEE_LIVER_CANCER_TOP50 8 1724 18519682 IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP 19 1724 18519682 IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN 19 1724 18519693 MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN 72 1724 18757432 BERNARD_PPAPDC1B_TARGETS_UP 13 1632 18757432 BERNARD_PPAPDC1B_TARGETS_DN 13 1632 18632645 GAURNIER_PSMD4_TARGETS 5 1694 18172260 EHLERS_ANEUPLOIDY_UP 10 1876 18157142 BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_DN 33 1876 18724378 HONMA_DOCETAXEL_RESISTANCE 11 1632 18806801 WILENSKY_RESPONSE_TO_DARAPLADIB 24 1602 18931683 BONCI_TARGETS_OF_MIR15A_AND_MIR16_1 98 1571 19029983 CHUNG_BLISTER_CYTOTOXICITY_UP 15 1541 19029983 CHUNG_BLISTER_CYTOTOXICITY_DN 15 1541 17210681 WHITEFORD_PEDIATRIC_CANCER_MARKERS 18 2241 17210682 GRADE_METASTASIS_DN 18 2241 17210682 GRADE_COLON_CANCER_UP 18 2241 17210682 GRADE_COLON_CANCER_DN 18 2241 17210682 GRADE_COLON_AND_RECTAL_CANCER_UP 18 2241 17210682 GRADE_COLON_AND_RECTAL_CANCER_DN 18 2241 17210682 GRADE_COLON_VS_RECTAL_CANCER_UP 18 2241 17210682 GRADE_COLON_VS_RECTAL_CANCER_DN 18 2241 15635089 BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN 25 2912 17210693 NAKAMURA_METASTASIS 11 2241 17210693 NAKAMURA_METASTASIS_MODEL_UP 11 2241 17210693 NAKAMURA_METASTASIS_MODEL_DN 11 2241 17210724 GRATIAS_RETINOBLASTOMA_16Q24 2 2241 17234769 WEST_ADRENOCORTICAL_TUMOR_UP 14 2241 17234769 WEST_ADRENOCORTICAL_TUMOR_DN 14 2241 17234769 WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_UP 14 2241 17234769 WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_DN 14 2241 17234778 CHO_NR4A1_TARGETS 18 2241 17234781 BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP 4 2241 17234781 BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN 4 2241 17234794 CLIMENT_BREAST_CANCER_COPY_NUMBER_UP 12 2241 17283119 SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_UP 25 2210 17308078 BRUECKNER_TARGETS_OF_MIRLET7A3_UP 52 2210 17308078 BRUECKNER_TARGETS_OF_MIRLET7A3_DN 52 2210 17308109 PODAR_RESPONSE_TO_ADAPHOSTIN_UP 12 2210 17308109 PODAR_RESPONSE_TO_ADAPHOSTIN_DN 12 2210 17308118 LU_TUMOR_ENDOTHELIAL_MARKERS_UP 16 2210 NaN LU_TUMOR_ANGIOGENESIS_UP NaN NaN 15757903 CHEN_HOXA5_TARGETS_9HR_UP 9 2851 15757903 CHEN_HOXA5_TARGETS_9HR_DN 9 2851 18849962 CONRAD_STEM_CELL 49 1571 18849962 CONRAD_GERMLINE_STEM_CELL 49 1571 17332321 KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION 10 2182 17332353 HUANG_DASATINIB_RESISTANCE_UP 53 2182 17332353 HUANG_DASATINIB_RESISTANCE_DN 53 2182 17363581 TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA 24 2182 17409404 CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 22 2151 17409404 CHNG_MULTIPLE_MYELOMA_HYPERPLOID_DN 22 2151 17409405 HUPER_BREAST_BASAL_VS_LUMINAL_UP 6 2151 17409405 HUPER_BREAST_BASAL_VS_LUMINAL_DN 6 2151 17409444 CUI_GLUCOSE_DEPRIVATION 4 2151 17409441 BLUM_RESPONSE_TO_SALIRASIB_UP 7 2151 17409441 BLUM_RESPONSE_TO_SALIRASIB_DN 7 2151 17409455 WINTER_HYPOXIA_METAGENE 34 2151 17409456 ALONSO_METASTASIS_EMT_UP 30 2151 NaN ALONSO_METASTASIS_NEURAL_UP NaN NaN 17409456 ALONSO_METASTASIS_UP 30 2151 17409456 ALONSO_METASTASIS_DN 30 2151 14676830 CROMER_TUMORIGENESIS_UP 34 3246 14676830 CROMER_TUMORIGENESIS_DN 34 3246 18724358 MUELLER_PLURINET 71 1632 18794900 FIRESTEIN_CTNNB1_PATHWAY 67 1632 18794900 FIRESTEIN_PROLIFERATION 67 1632 17440068 JIANG_TIP30_TARGETS_UP 6 2151 17440068 JIANG_TIP30_TARGETS_DN 6 2151 17440070 GRESHOCK_CANCER_COPY_NUMBER_UP 14 2151 17440070 GRESHOCK_CANCER_COPY_NUMBER_DN 14 2151 17440099 TSAI_RESPONSE_TO_RADIATION_THERAPY 18 2151 17483311 BEIER_GLIOMA_STEM_CELL_UP 116 2121 17483311 BEIER_GLIOMA_STEM_CELL_DN 116 2121 17483315 VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP 22 2121 17483315 VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN 22 2121 12947006 DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN 29 3368 17456585 WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER 4 2121 15958647 FERRARI_RESPONSE_TO_FENRETINIDE_UP 9 2820 17483324 HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS 19 2121 17483333 GU_PDEF_TARGETS_UP 17 2121 17483333 GU_PDEF_TARGETS_DN 17 2121 17483357 TOOKER_GEMCITABINE_RESISTANCE_UP 2 2121 17483357 TOOKER_GEMCITABINE_RESISTANCE_DN 2 2121 17483357 TOOKER_RESPONSE_TO_BEXAROTENE_UP 2 2121 17483357 TOOKER_RESPONSE_TO_BEXAROTENE_DN 2 2121 17195838 BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP 17 2241 17195838 BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN 17 2241 16627760 FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP 12 2394 16627760 FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_DN 12 2394 17334370 SPIRA_SMOKERS_LUNG_CANCER_UP 57 2182 17334370 SPIRA_SMOKERS_LUNG_CANCER_DN 57 2182 17767167 WAGNER_APO2_SENSITIVITY 58 1998 12480690 CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP 11 3582 12480690 CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN 11 3582 14973112 FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP 66 3306 14973112 FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN 66 3306 12356685 LINDSTEDT_DENDRITIC_CELL_MATURATION_A 4 3794 12356685 LINDSTEDT_DENDRITIC_CELL_MATURATION_B 4 3794 12356685 LINDSTEDT_DENDRITIC_CELL_MATURATION_C 4 3794 12356685 LINDSTEDT_DENDRITIC_CELL_MATURATION_D 4 3794 15339848 NICK_RESPONSE_TO_PROC_TREATMENT_DN 48 3002 12670911 NUTT_GBM_VS_AO_GLIOMA_UP 93 3612 12670911 NUTT_GBM_VS_AO_GLIOMA_DN 93 3612 12893766 PARK_APL_PATHOGENESIS_UP 23 3398 12893766 PARK_APL_PATHOGENESIS_DN 23 3398 12893766 PARK_TRETINOIN_RESPONSE_AND_PML_RARA_FUSION 23 3398 12893766 PARK_TRETINOIN_RESPONSE_AND_RARA_PLZF_FUSION 23 3398 15619625 ZHANG_INTERFERON_RESPONSE 54 2971 16116430 WU_ALZHEIMER_DISEASE_DN 30 2728 16127434 MIZUKAMI_HYPOXIA_UP 70 2728 17057710 POTTI_CYTOXAN_SENSITIVITY 90 2302 15155749 RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP 7 3124 15155749 RAY_TARGETS_OF_P210_BCR_ABL_FUSION_DN 7 3124 15492259 RUIZ_TNC_TARGETS_UP 10 3063 15492259 RUIZ_TNC_TARGETS_DN 10 3063 16527888 RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP 27 2425 16527888 RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN 27 2425 16527888 RUTELLA_RESPONSE_TO_HGF_UP 27 2425 16527888 RUTELLA_RESPONSE_TO_HGF_DN 27 2425 16527888 RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP 27 2425 16527888 RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN 27 2425 14737219 CHANG_CORE_SERUM_RESPONSE_UP 166 3306 14737219 CHANG_CORE_SERUM_RESPONSE_DN 166 3306 14737219 CHANG_CYCLING_GENES 166 3306 15024077 MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_UP 31 3246 15024077 MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_DN 31 3246 15226186 ROSS_LEUKEMIA_WITH_MLL_FUSIONS 66 3002 11823860 VANTVEER_BREAST_CANCER_ESR1_UP 1182 4067 11823860 VANTVEER_BREAST_CANCER_ESR1_DN 1182 4067 11823860 VANTVEER_BREAST_CANCER_BRCA1_UP 1182 4067 11823860 VANTVEER_BREAST_CANCER_BRCA1_DN 1182 4067 NaN WALLACE_JAK2_TARGETS_UP NaN NaN 15199222 AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_UP 64 3185 15199222 AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_DN 64 3185 15608639 SWEET_KRAS_ONCOGENIC_SIGNATURE 98 2971 12673201 HINATA_NFKB_TARGETS_KERATINOCYTE_UP 23 3612 12673201 HINATA_NFKB_TARGETS_KERATINOCYTE_DN 23 3612 NaN HINATA_NFKB_TARGETS_FIBROBLAST_UP NaN NaN 12411319 HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP 12 3763 12411319 HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_DN 12 3763 12411319 HOFMANN_MYELODYSPLASTIC_SYNDROM_HIGH_RISK_DN 12 3763 12411319 HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP 12 3763 12411319 HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_DN 12 3763 15210650 LEE_EARLY_T_LYMPHOCYTE_UP 15 3124 15210650 LEE_EARLY_T_LYMPHOCYTE_DN 15 3124 15210650 LEE_INTRATHYMIC_T_PROGENITOR 15 3124 15210650 LEE_DOUBLE_POLAR_THYMOCYTE 15 3124 15210650 LEE_RECENT_THYMIC_EMIGRANT 15 3124 15210650 LEE_DIFFERENTIATING_T_LYMPHOCYTE 15 3124 12057921 LI_WILMS_TUMOR 33 3916 18438415 FINAK_BREAST_CANCER_SDPP_SIGNATURE 162 1755 18641660 SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 121 1663 18641660 SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4 121 1663 18641660 SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5 121 1663 18288197 MELLMAN_TUT1_TARGETS_UP 25 1845 18288197 MELLMAN_TUT1_TARGETS_DN 25 1845 18337816 HAN_SATB1_TARGETS_UP 66 1816 18337816 HAN_SATB1_TARGETS_DN 66 1816 18641660 SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12 121 1663 18568025 SHAFFER_IRF4_MULTIPLE_MYELOMA_PROGRAM 62 1694 18568025 SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE 62 1694 18568025 SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE 62 1694 18568025 SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE 62 1694 18568025 SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL 62 1694 11773596 HSIAO_HOUSEKEEPING_GENES 83 4098 18185580 TAVAZOIE_METASTASIS 231 1876 NaN WENDT_COHESIN_TARGETS_UP NaN NaN 12086890 FERRANDO_HOX11_NEIGHBORS 110 4036 12704389 CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_HD_MTX_DN 31 3582 12393520 ZHAN_EARLY_DIFFERENTIATION_GENES_DN 22 3671 18676865 LIU_VAV3_PROSTATE_CARCINOGENESIS_UP 5 1663 18676865 LIU_VAV3_PROSTATE_CARCINOGENESIS_DN 5 1663 12791645 CROONQUIST_IL6_DEPRIVATION_UP 13 3429 12791645 CROONQUIST_IL6_DEPRIVATION_DN 13 3429 12791645 CROONQUIST_STROMAL_STIMULATION_UP 13 3429 12791645 CROONQUIST_NRAS_SIGNALING_UP 13 3429 12791645 CROONQUIST_NRAS_SIGNALING_DN 13 3429 12791645 CROONQUIST_NRAS_VS_STROMAL_STIMULATION_UP 13 3429 12791645 CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN 13 3429 12393520 ZHAN_LATE_DIFFERENTIATION_GENES_UP 22 3671 12393520 ZHAN_LATE_DIFFERENTIATION_GENES_DN 22 3671 12393520 ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_UP 22 3671 12393520 ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_DN 22 3671 12393520 ZHAN_V1_LATE_DIFFERENTIATION_GENES_UP 22 3671 12393520 ZHAN_V1_LATE_DIFFERENTIATION_GENES_DN 22 3671 12621037 ROME_INSULIN_TARGETS_IN_MUSCLE_UP 23 3582 12621037 ROME_INSULIN_TARGETS_IN_MUSCLE_DN 23 3582 15084694 VALK_AML_CLUSTER_1 153 3246 15084694 VALK_AML_CLUSTER_2 153 3246 15084694 VALK_AML_CLUSTER_3 153 3246 15084694 VALK_AML_CLUSTER_4 153 3246 15084694 VALK_AML_CLUSTER_5 153 3246 15084694 VALK_AML_CLUSTER_6 153 3246 15084694 VALK_AML_CLUSTER_7 153 3246 15084694 VALK_AML_CLUSTER_8 153 3246 15084694 VALK_AML_CLUSTER_9 153 3246 15084694 VALK_AML_CLUSTER_10 153 3246 15084694 VALK_AML_CLUSTER_11 153 3246 15084694 VALK_AML_CLUSTER_12 153 3246 15084694 VALK_AML_CLUSTER_13 153 3246 15084694 VALK_AML_CLUSTER_15 153 3246 15084694 VALK_AML_CLUSTER_16 153 3246 15084694 VALK_AML_WITH_11Q23_REARRANGED 153 3246 15084694 VALK_AML_WITH_EVI1 153 3246 15084694 VALK_AML_WITH_CEBPA 153 3246 15084694 VALK_AML_WITH_FLT3_ITD 153 3246 15031206 JISON_SICKLE_CELL_DISEASE_UP 37 3155 15031206 JISON_SICKLE_CELL_DISEASE_DN 37 3155 15864312 POOLA_INVASIVE_BREAST_CANCER_UP 25 2851 15864312 POOLA_INVASIVE_BREAST_CANCER_DN 25 2851 18948947 DING_LUNG_CANCER_BY_MUTATION_RATE 285 1602 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G1_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G2 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G12_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G56_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G56_DN 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP 58 2241 17187432 BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN 58 2241 18701503 CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_UP 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_DN 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_UP 29 1663 18701503 CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN 29 1663 18506891 COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP 29 1724 18506891 COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN 29 1724 18923165 HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_UP 90 1571 18923165 HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN 90 1571 18923165 HOSHIDA_LIVER_CANCER_SURVIVAL_UP 90 1571 18923165 HOSHIDA_LIVER_CANCER_SURVIVAL_DN 90 1571 16710476 KAPOSI_LIVER_CANCER_POOR_SURVIVAL_UP 47 2455 18316609 YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 55 1816 18316609 YAMASHITA_LIVER_CANCER_WITH_EPCAM_DN 55 1816 19150350 YAMASHITA_LIVER_CANCER_STEM_CELL_UP 70 1451 19150350 YAMASHITA_LIVER_CANCER_STEM_CELL_DN 70 1451 16532004 LEE_LIVER_CANCER_HEPATOBLAST 105 2516 17975138 WANG_RECURRENT_LIVER_CANCER_UP 5 1937 17975138 WANG_RECURRENT_LIVER_CANCER_DN 5 1937 18381945 WOO_LIVER_CANCER_RECURRENCE_UP 12 1785 18381945 WOO_LIVER_CANCER_RECURRENCE_DN 12 1785 NaN YAMANAKA_GLIOBLASTOMA_SURVIVAL_UP NaN NaN 12738660 YAGI_AML_WITH_T_8_21_TRANSLOCATION 20 3459 12738660 YAGI_AML_WITH_INV_16_TRANSLOCATION 20 3459 12738660 YAGI_AML_WITH_T_9_11_TRANSLOCATION 20 3459 12738660 YAGI_AML_WITH_11Q23_REARRANGED 20 3459 19167881 YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_UP 3 1451 19167881 YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_DN 3 1451 15288478 KUROKAWA_LIVER_CANCER_EARLY_RECURRENCE_UP 10 3124 18505969 SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_UP 35 1724 18505969 SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_DN 35 1724 17623797 KESHELAVA_MULTIPLE_DRUG_RESISTANCE 7 2060 16595783 WINNEPENNINCKX_MELANOMA_METASTASIS_DN 58 2516 16788156 TSAI_DNAJB4_TARGETS_UP 14 2455 16954472 ASGHARZADEH_NEUROBLASTOMA_POOR_SURVIVAL_DN 27 2363 15657340 LI_PROSTATE_CANCER_EPIGENETIC 40 2971 16077073 UROSEVIC_RESPONSE_TO_IMIQUIMOD 23 2759 17968324 FONTAINE_FOLLICULAR_THYROID_ADENOMA_UP 5 1785 17968324 FONTAINE_FOLLICULAR_THYROID_ADENOMA_DN 5 1785 17968324 FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_UP 5 1785 17968324 FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_DN 5 1785 17968324 FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP 5 1785 17968324 FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN 5 1785 17334365 WEBER_METHYLATED_LCP_IN_FIBROBLAST_UP 335 2151 17334365 WEBER_METHYLATED_ICP_IN_FIBROBLAST 335 2151 17334365 WEBER_METHYLATED_LCP_IN_SPERM_UP 335 2151 17922014 PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP 88 1937 16116479 SYED_ESTRADIOL_RESPONSE 1 2637 18974123 STEIN_ESR1_TARGETS 18 1571 18974123 STEIN_ESRRA_TARGETS 18 1571 18974123 STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA 18 1571 19074895 SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP 3 1541 16540645 LOPEZ_EPITHELIOID_MESOTHELIOMA 17 2547 16540645 LOPEZ_MESOTHELIOMA_SURVIVAL_OVERALL_DN 17 2547 16540645 LOPEZ_MESOTHELIOMA_SURVIVAL_UP 17 2547 16540645 LOPEZ_MESOTHELIOMA_SURVIVAL_DN 17 2547 16424014 KORKOLA_CORRELATED_WITH_POU5F1 39 2606 16424014 KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_UP 39 2606 16424014 KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_DN 39 2606 17145885 KOBAYASHI_EGFR_SIGNALING_24HR_UP 20 2272 17145885 KOBAYASHI_EGFR_SIGNALING_24HR_DN 20 2272 16849555 FOURNIER_ACINAR_DEVELOPMENT_LATE_2 31 2425 19723656 HOSHIDA_LIVER_CANCER_SUBCLASS_S1 31 1267 19723656 HOSHIDA_LIVER_CANCER_SUBCLASS_S2 31 1267 19723656 HOSHIDA_LIVER_CANCER_SUBCLASS_S3 31 1267 17510386 PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP 45 2121 17510386 PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_DN 45 2121 19061838 CAIRO_HEPATOBLASTOMA_UP 17 1541 19061838 CAIRO_HEPATOBLASTOMA_DN 17 1541 19061838 CAIRO_HEPATOBLASTOMA_CLASSES_UP 17 1541 19061838 CAIRO_HEPATOBLASTOMA_CLASSES_DN 17 1541 19061838 CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL 17 1541 17252022 GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP 18 2182 17252022 GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN 18 2182 17252022 GUTIERREZ_MULTIPLE_MYELOMA_DN 18 2182 16595783 WINNEPENNINCKX_MELANOMA_METASTASIS_UP 58 2516 16914566 HAHTOLA_CTCL_CUTANEOUS 3 2394 16914566 HAHTOLA_CTCL_PATHOGENESIS 3 2394 16606835 UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN 15 2516 11823860 VANTVEER_BREAST_CANCER_POOR_PROGNOSIS 1182 4067 14684422 CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY 28 3246 14684422 CHIARETTI_T_ALL_RELAPSE_PROGNOSIS 28 3246 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD2_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_LB_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_HP_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_MF_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_MS_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_PR_DN 101 2363 14519204 DANG_REGULATED_BY_MYC_UP 88 NaN 14519204 DANG_REGULATED_BY_MYC_DN 88 NaN 14519204 DANG_MYC_TARGETS_UP 88 NaN 14519204 DANG_MYC_TARGETS_DN 88 NaN 15681441 DORN_ADENOVIRUS_INFECTION_12HR_UP 7 2940 15681441 DORN_ADENOVIRUS_INFECTION_12HR_DN 7 2940 15681441 DORN_ADENOVIRUS_INFECTION_24HR_DN 7 2940 15681441 DORN_ADENOVIRUS_INFECTION_32HR_DN 7 2940 15681441 DORN_ADENOVIRUS_INFECTION_48HR_UP 7 2940 15681441 DORN_ADENOVIRUS_INFECTION_48HR_DN 7 2940 15722553 TIAN_TNF_SIGNALING_VIA_NFKB 41 2881 15722553 TIAN_TNF_SIGNALING_NOT_VIA_NFKB 41 2881 18397753 WONG_EMBRYONIC_STEM_CELL_CORE 106 1785 17464315 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 13 2060 17464315 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_DN 13 2060 17464315 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP 13 2060 17464315 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN 13 2060 17430594 CHANDRAN_METASTASIS_UP 48 NaN 17430594 CHANDRAN_METASTASIS_DN 48 NaN 16912175 SENGUPTA_EBNA1_ANTICORRELATED 25 2394 12808457 MOOTHA_FFA_OXYDATION 713 3521 12808457 MOOTHA_GLUCONEOGENESIS 713 3521 12808457 MOOTHA_GLYCOGEN_METABOLISM 713 3521 12808457 MOOTHA_GLYCOLYSIS 713 3521 17009164 HO_LIVER_CANCER_VASCULAR_INVASION 3 2302 11532376 MURAKAMI_UV_RESPONSE_1HR_UP 7 4159 12771951 DAZARD_UV_RESPONSE_CLUSTER_G24 16 3582 11965276 NIELSEN_GIST 82 3977 15095275 DASU_IL6_SIGNALING_UP 10 3246 12692265 JIANG_HYPOXIA_VIA_VHL 23 3612 12138103 WU_APOPTOSIS_BY_CDKN1A_VIA_TP53 17 3824 12138103 WU_APOPTOSIS_BY_CDKN1A_NOT_VIA_TP53 17 3824 15026540 SASSON_RESPONSE_TO_GONADOTROPHINS_UP 8 3216 15026540 SASSON_RESPONSE_TO_GONADOTROPHINS_DN 8 3216 15026540 SASSON_RESPONSE_TO_FORSKOLIN_UP 8 3216 15026540 SASSON_RESPONSE_TO_FORSKOLIN_DN 8 3216 11711622 BROWNE_HCMV_INFECTION_30MIN_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_30MIN_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_1HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_1HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_2HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_2HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_4HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_4HR_DN 95 4098 17353439 RAGHAVACHARI_PLATELET_SPECIFIC_GENES 11 2182 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_PR_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_LB_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_MS_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_HP_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD1_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_CD2_UP 101 2363 16728703 ZHAN_MULTIPLE_MYELOMA_MF_UP 101 2363 15051823 URS_ADIPOCYTE_DIFFERENTIATION_DN 18 3246 15051823 URS_ADIPOCYTE_DIFFERENTIATION_UP 18 3246 11309484 KAYO_AGING_MUSCLE_DN 46 4342 11309484 KAYO_AGING_MUSCLE_UP 46 4342 15190254 LU_AGING_BRAIN_DN 221 3185 15190254 LU_AGING_BRAIN_UP 221 3185 15562319 RODWELL_AGING_KIDNEY_DN 43 3002 15562319 RODWELL_AGING_KIDNEY_NO_BLOOD_DN 43 3002 15562319 RODWELL_AGING_KIDNEY_NO_BLOOD_UP 43 3002 15562319 RODWELL_AGING_KIDNEY_UP 43 3002 14769913 BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN 133 3306 14769913 BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP 133 3306 15103417 KAAB_HEART_ATRIUM_VS_VENTRICLE_UP 10 3216 16135788 WANG_SMARCE1_TARGETS_DN 12 2728 16135788 WANG_SMARCE1_TARGETS_UP 12 2728 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_DN 3 2790 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_DN 3 2790 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_UP 3 2790 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_24HR_UP 3 2790 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_DN 3 2790 15980968 BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_UP 3 2790 12610208 HEDENFALK_BREAST_CANCER_BRACX_DN 27 3643 12610208 HEDENFALK_BREAST_CANCER_BRACX_UP 27 3643 10644742 MACLACHLAN_BRCA1_TARGETS_DN 27 4798 10644742 MACLACHLAN_BRCA1_TARGETS_UP 27 4798 12096084 JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN 30 3886 12096084 JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP 30 3886 11207349 HEDENFALK_BREAST_CANCER_HEREDITARY_VS_SPORADIC 182 4401 11207349 HEDENFALK_BREAST_CANCER_BRCA1_VS_BRCA2 182 4401 14673169 HENDRICKS_SMARCA4_TARGETS_DN 32 3337 14673169 HENDRICKS_SMARCA4_TARGETS_UP 32 3337 11423116 DELLA_RESPONSE_TO_TSA_AND_BUTYRATE 18 4281 11309484 KAYO_CALORIE_RESTRICTION_MUSCLE_DN 46 4342 11309484 KAYO_CALORIE_RESTRICTION_MUSCLE_UP 46 4342 15184677 RHODES_CANCER_META_SIGNATURE 199 3185 15184677 RHODES_UNDIFFERENTIATED_CANCER 199 3185 14639605 ZHANG_RESPONSE_TO_CANTHARIDIN_DN 2 3337 14639605 ZHANG_RESPONSE_TO_CANTHARIDIN_UP 2 3337 15869869 MCLACHLAN_DENTAL_CARIES_DN 5 2728 15869869 MCLACHLAN_DENTAL_CARIES_UP 5 2728 14737109 WHITESIDE_CISPLATIN_RESISTANCE_DN 2 3337 14737109 WHITESIDE_CISPLATIN_RESISTANCE_UP 2 3337 15107491 WANG_CISPLATIN_RESPONSE_AND_XPC_DN 7 NaN 15107491 WANG_CISPLATIN_RESPONSE_AND_XPC_UP 7 NaN 9826724 ZHU_CMV_24_HR_DN 126 5224 9826724 ZHU_CMV_24_HR_UP 126 5224 9826724 ZHU_CMV_8_HR_DN 126 5224 9826724 ZHU_CMV_8_HR_UP 126 5224 9826724 ZHU_CMV_ALL_DN 126 5224 9826724 ZHU_CMV_ALL_UP 126 5224 11711622 BROWNE_HCMV_INFECTION_6HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_6HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_10HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_10HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_12HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_12HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_14HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_14HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_16HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_16HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_18HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_18HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_20HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_20HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_24HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_24HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_48HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_48HR_UP 95 4098 11711622 BROWNE_HCMV_INFECTION_8HR_DN 95 4098 11711622 BROWNE_HCMV_INFECTION_8HR_UP 95 4098 11867723 SONG_TARGETS_OF_IE86_CMV_PROTEIN 33 4008 11861364 LIANG_SILENCED_BY_METHYLATION_2 18 4036 11861364 LIANG_SILENCED_BY_METHYLATION_DN 18 4036 11861364 LIANG_SILENCED_BY_METHYLATION_UP 18 4036 12839967 SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2 52 3521 12839967 SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1 52 3521 15042541 BAELDE_DIABETIC_NEPHROPATHY_DN 22 3246 15042541 BAELDE_DIABETIC_NEPHROPATHY_UP 22 3246 NaN ZHANG_PROLIFERATING_VS_QUIESCENT NaN NaN 11755394 MARTINEZ_RESPONSE_TO_TRABECTEDIN 8 4098 12198119 GAJATE_RESPONSE_TO_TRABECTEDIN_DN 11 3763 12198119 GAJATE_RESPONSE_TO_TRABECTEDIN_UP 11 3763 15661559 MARCHINI_TRABECTEDIN_RESISTANCE_DN 2 2971 15661559 MARCHINI_TRABECTEDIN_RESISTANCE_UP 2 2971 15897246 MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN 12 2851 15897246 MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP 12 2851 15386376 JI_RESPONSE_TO_FSH_DN 5 3002 15386376 JI_RESPONSE_TO_FSH_UP 5 3002 15845533 XU_GH1_AUTOCRINE_TARGETS_DN 2 2820 15845533 XU_GH1_AUTOCRINE_TARGETS_UP 2 2820 15845533 XU_GH1_EXOGENOUS_TARGETS_DN 2 2820 15845533 XU_GH1_EXOGENOUS_TARGETS_UP 2 2820 11439330 WU_HBX_TARGETS_1_DN 9 4281 11439330 WU_HBX_TARGETS_1_UP 9 4281 11439330 WU_HBX_TARGETS_3_DN 9 4281 11439330 WU_HBX_TARGETS_3_UP 9 4281 11439330 WU_HBX_TARGETS_2_DN 9 4281 11439330 WU_HBX_TARGETS_2_UP 9 4281 10969808 MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_5 62 4585 15103417 KAAB_FAILED_HEART_ATRIUM_DN 10 3216 15103417 KAAB_FAILED_HEART_ATRIUM_UP 10 3216 15103417 KAAB_FAILED_HEART_VENTRICLE_DN 10 3216 15231652 GEORGANTAS_HSC_MARKERS 17 3155 10741968 LY_AGING_PREMATURE_DN 76 4738 11516994 SEMENZA_HIF1_TARGETS 83 4220 10756030 CHANG_IMMORTALIZED_BY_HPV31_DN 49 4677 10756030 CHANG_IMMORTALIZED_BY_HPV31_UP 49 4677 11904358 SU_KIDNEY 413 3977 11904358 SU_LIVER 413 3977 11904358 SU_PANCREAS 413 3977 11904358 SU_PLACENTA 413 3977 11904358 SU_SALIVARY_GLAND 413 3977 11904358 SU_TESTIS 413 3977 11904358 SU_THYMUS 413 3977 16007088 WEBER_METHYLATED_IN_COLON_CANCER 270 2759 12692265 JIANG_HYPOXIA_NORMAL 23 3612 12692265 JIANG_HYPOXIA_CANCER 23 3612 12885785 LEONARD_HYPOXIA 21 3429 11902584 HARRIS_HYPOXIA 387 4067 11741835 EHRLICH_ICF_SYNDROM_DN 15 4098 12414529 TRACEY_RESISTANCE_TO_IFNA2_DN 9 3763 11711622 BROWNE_INTERFERON_RESPONSIVE_GENES 95 4098 16140920 NATSUME_RESPONSE_TO_INTERFERON_BETA_DN 12 2728 16140920 NATSUME_RESPONSE_TO_INTERFERON_BETA_UP 12 2728 12091409 MAHAJAN_RESPONSE_TO_IL1A_DN 4 3886 12091409 MAHAJAN_RESPONSE_TO_IL1A_UP 4 3886 15095275 DASU_IL6_SIGNALING_SCAR_DN 10 3246 15095275 DASU_IL6_SIGNALING_SCAR_UP 10 3246 12471561 ABE_INNER_EAR 18 3702 12824457 CHEN_LVAD_SUPPORT_OF_FAILING_HEART_DN 13 3490 12824457 CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP 13 3490 12469122 RAMASWAMY_METASTASIS_DN 349 3702 12469122 RAMASWAMY_METASTASIS_UP 349 3702 10741968 LY_AGING_MIDDLE_DN 76 4738 10741968 LY_AGING_MIDDLE_UP 76 4738 NaN MMS_MOUSE_LYMPH_HIGH_4HRS_UP NaN NaN 12036489 KRASNOSELSKAYA_ILF3_TARGETS_DN 16 3947 12036489 KRASNOSELSKAYA_ILF3_TARGETS_UP 16 3947 12915101 CHENG_RESPONSE_TO_NICKEL_ACETATE 3 3490 12479369 BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN 2 3886 12479369 BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_UP 2 3886 10741968 LY_AGING_OLD_DN 76 4738 12414654 CHUANG_OXIDATIVE_STRESS_RESPONSE_UP 16 3763 12419474 WEIGEL_OXIDATIVE_STRESS_RESPONSE 13 3763 12419474 WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2 13 3763 12419474 WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2 13 3763 12419474 WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_TBH 13 3763 12446780 INGA_TP53_TARGETS 43 3733 15033468 KIM_GASTRIC_CANCER_CHEMOSENSITIVITY 7 3246 12885910 DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN 16 3490 12885910 DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP 16 3490 NaN TRAYNOR_RETT_SYNDROM_UP NaN NaN 12719586 ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN 24 3582 12719586 ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP 24 3582 11279127 VERRECCHIA_RESPONSE_TO_TGFB1_C1 64 4312 11279127 VERRECCHIA_RESPONSE_TO_TGFB1_C2 64 4312 11279127 VERRECCHIA_RESPONSE_TO_TGFB1_C3 64 4312 11279127 VERRECCHIA_RESPONSE_TO_TGFB1_C4 64 4312 11279127 VERRECCHIA_RESPONSE_TO_TGFB1_C5 64 4312 11279127 VERRECCHIA_EARLY_RESPONSE_TO_TGFB1 64 4312 11279127 VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 64 4312 12839967 SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER 52 3521 14606959 MOREIRA_RESPONSE_TO_TSA_DN 20 3398 14606959 MOREIRA_RESPONSE_TO_TSA_UP 20 3398 15452378 CHIBA_RESPONSE_TO_TSA_DN 10 NaN 15452378 CHIBA_RESPONSE_TO_TSA_UP 10 NaN 15336447 CHIBA_RESPONSE_TO_TSA 10 3093 12839967 SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER 52 3521 12771951 DAZARD_UV_RESPONSE_CLUSTER_G1 16 3582 12771951 DAZARD_UV_RESPONSE_CLUSTER_G2 16 3582 12771951 DAZARD_UV_RESPONSE_CLUSTER_G3 16 3582 12771951 DAZARD_UV_RESPONSE_CLUSTER_G4 16 3582 12771951 DAZARD_UV_RESPONSE_CLUSTER_G6 16 3582 12771951 DAZARD_RESPONSE_TO_UV_NHEK_DN 16 3582 12771951 DAZARD_RESPONSE_TO_UV_NHEK_UP 16 3582 11982916 TAKAO_RESPONSE_TO_UVB_RADIATION_DN 5 4036 11982916 TAKAO_RESPONSE_TO_UVB_RADIATION_UP 5 4036 11867738 SESTO_RESPONSE_TO_UV_C0 23 4008 11867738 SESTO_RESPONSE_TO_UV_C1 23 4008 11867738 SESTO_RESPONSE_TO_UV_C2 23 4008 11867738 SESTO_RESPONSE_TO_UV_C3 23 4008 11867738 SESTO_RESPONSE_TO_UV_C4 23 4008 11867738 SESTO_RESPONSE_TO_UV_C5 23 4008 11867738 SESTO_RESPONSE_TO_UV_C6 23 4008 11867738 SESTO_RESPONSE_TO_UV_C7 23 4008 11867738 SESTO_RESPONSE_TO_UV_C8 23 4008 11532376 MURAKAMI_UV_RESPONSE_24HR 7 4159 11532376 MURAKAMI_UV_RESPONSE_6HR_DN 7 4159 11532376 MURAKAMI_UV_RESPONSE_6HR_UP 7 4159 12771951 DAZARD_RESPONSE_TO_UV_SCC_DN 16 3582 12771951 DAZARD_RESPONSE_TO_UV_SCC_UP 16 3582 12907719 GENTILE_UV_HIGH_DOSE_DN 15 3490 12907719 GENTILE_UV_HIGH_DOSE_UP 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D1 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D2 15 3490 12907719 GENTILE_RESPONSE_CLUSTER_D3 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D4 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D5 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D6 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D7 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D8 15 3490 12907719 GENTILE_UV_RESPONSE_CLUSTER_D9 15 3490 12907719 GENTILE_UV_LOW_DOSE_DN 15 3490 12907719 GENTILE_UV_LOW_DOSE_UP 15 3490 12197474 ABE_VEGFA_TARGETS_2HR 14 NaN 12197474 ABE_VEGFA_TARGETS_30MIN 14 NaN 12197474 ABE_VEGFA_TARGETS 14 NaN 15103417 KAAB_HEART_ATRIUM_VS_VENTRICLE_DN 10 3216 12692265 JIANG_VHL_TARGETS 23 3612 12808457 MOOTHA_HUMAN_MITODB_6_2002 713 3521 12808457 MOOTHA_MITOCHONDRIA 713 3521 12808457 MOOTHA_PGC 713 3521 12808457 MOOTHA_TCA 713 3521 15469929 NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_DN 55 3063 15469929 NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_UP 55 3063 15608061 ZUCCHI_METASTASIS_DN 12 3002 15608061 ZUCCHI_METASTASIS_UP 12 3002 15349906 LEE_LIVER_CANCER_SURVIVAL_DN 83 3093 15349906 LEE_LIVER_CANCER_SURVIVAL_UP 83 3093 15930281 ZHANG_TARGETS_OF_EWSR1_FLI1_FUSION 20 2820